Systematic review of the effectiveness of preventing and treating Staphylococcus aureus carriage in reducing peritoneal catheter-related infections by McCormack, Kirsty et al.
Systematic review of the effectiveness of
preventing and treating Staphylococcus
aureus carriage in reducing peritoneal
catheter-related infections
K McCormack, K Rabindranath, M Kilonzo, 
L Vale, C Fraser, L McIntyre, S Thomas, 
H Rothnie, N Fluck, IM Gould and N Waugh
Health Technology Assessment 2007; Vol. 11: No. 23
HTA
Health Technology Assessment
NHS R&D HTA Programme
www.hta.ac.uk
The National Coordinating Centre for Health Technology Assessment,
Mailpoint 728, Boldrewood,
University of Southampton,
Southampton, SO16 7PX, UK.
Fax: +44 (0) 23 8059 5639 Email: hta@hta.ac.uk
http://www.hta.ac.uk ISSN 1366-5278
Feedback
The HTA Programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website
(http://www.hta.ac.uk) is a convenient way to publish 
your comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.
July 2007
H
e
a
l
t
h
 
T
e
c
h
n
o
l
o
g
y
 
A
s
s
e
s
s
m
e
n
t
 
2
0
0
7
;
V
o
l
.
 
1
1
:
 
N
o
.
 
2
3
R
e
d
u
c
i
n
g
 
p
e
r
i
t
o
n
e
a
l
 
c
a
t
h
e
t
e
r
-
r
e
l
a
t
e
d
 
i
n
f
e
c
t
i
o
n
sHow to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of
charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is
also available (see below). 
Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and
private sector purchasers from our Despatch Agents.
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is
£2 per monograph and for the rest of the world £3 per monograph.
You can order HTA monographs from our Despatch Agents:
– fax (with credit card or official purchase order) 
– post (with credit card or official purchase order or cheque)
– phone during office hours (credit card only).
Additionally the HTA website allows you either to pay securely by credit card or to print out your
order and then post or fax it.
Contact details are as follows:
HTA Despatch Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, HAVANT PO9 2NP , UK Fax from outside the UK: +44 2392 478 555
NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of 
£100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 
per volume. Please see our website for details. Subscriptions can only be purchased for the current or
forthcoming volume.
Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd
and drawn on a bank with a UK address.
Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard,
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.
Paying by official purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.
How do I get a copy of HTA on CD?
Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see
contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.
The website also provides information about the HTA Programme and lists the membership of the various
committees.
HTAHow to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of
charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is
also available (see below). 
Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and
private sector purchasers from our Despatch Agents.
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is
£2 per monograph and for the rest of the world £3 per monograph.
You can order HTA monographs from our Despatch Agents:
– fax (with credit card or ofﬁcial purchase order) 
– post (with credit card or ofﬁcial purchase order or cheque)
– phone during ofﬁce hours (credit card only).
Additionally the HTA website allows you either to pay securely by credit card or to print out your
order and then post or fax it.
Contact details are as follows:
HTA Publications Email: orders@hta.ac.uk
PO Box 642 Tel: 0870 1616662
YORK YO31 7WX Fax: 0870 1616663
UK
NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of 
£100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 
per volume. Please see our website for details. Subscriptions can only be purchased for the current or
forthcoming volume.
Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling. Please see our website for details.
Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard,
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.
Paying by ofﬁcial purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.
How do I get a copy of HTA on CD?
Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact our despatch agents
(see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge 
worldwide.
The website also provides information about the HTA Programme and lists the membership of the various
committees.
HTASystematic review of the effectiveness of
preventing and treating Staphylococcus
aureus carriage in reducing peritoneal
catheter-related infections
K McCormack,1* K Rabindranath,2 M Kilonzo,3
L Vale,1,3 C Fraser,1 L McIntyre,4 S Thomas,4
H Rothnie,4 N Fluck,5 IM Gould6 and N Waugh7
1 Health Services Research Unit, Institute of Applied Health Sciences,
University of Aberdeen, UK
2 Department of Renal Medicine, Churchill Hospital, Oxford, UK
3 Health Economics Research Unit, Institute of Applied Health Sciences,
University of Aberdeen, UK
4 Systematic Reviewer, Orkney, UK
5 Department of Renal Medicine, Aberdeen Royal Infirmary, UK
6 Medical Microbiology, Aberdeen Royal Infirmary, UK
7 Department of Public Health, University of Aberdeen, UK
* Corresponding author
Declared competing interests of authors: none
Published July 2007
This report should be referenced as follows:
McCormack K, Rabindranath K, Kilonzo M, Vale L, Fraser C, McIntyre L, et al. Systematic
review of the effectiveness of preventing and treating Staphylococcus aureus carriage in
reducing peritoneal catheter-related infections. Health Technol Assess 2007;11(23).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE,
Excerpta Medica/EMBASE and Science Citation Index Expanded (SciSearch®) and 
Current Contents®/Clinical Medicine.NIHR Health Technology Assessment Programme
T
he Health Technology Assessment (HTA) programme, now part of the National Institute for Health
Research (NIHR), was set up in 1993. It produces high-quality research information on the costs,
effectiveness and broader impact of health technologies for those who use, manage and provide care in
the NHS. ‘Health technologies’ are broadly defined to include all interventions used to promote health,
prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.
The research findings from the HTA Programme directly influence decision-making bodies such as the
National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee
(NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that
they form a key component of the ‘National Knowledge Service’.
The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are
three routes to the start of projects. 
First is the commissioned route. Suggestions for research are actively sought from people working in the
NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts.
These suggestions are carefully prioritised by panels of independent experts (including NHS service
users). The HTA Programme then commissions the research by competitive tender. 
Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research
questions. These are assessed for importance to patients and the NHS, and scientific rigour.
Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme
commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring 
together evidence on the value of specific technologies.
Some HTA research projects, including TARs, may take only months, others need several years. They can
cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence,
undertaking a trial, or other research collecting new data to answer a research problem.
The final reports from HTA projects are peer-reviewed by a number of independent expert referees
before publication in the widely read monograph series Health Technology Assessment. 
Criteria for inclusion in the HTA monograph series
Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA
Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search,
appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the
replication of the review by others.
The research reported in this monograph was commissioned by the HTA Programme as project number
05/29/01. The contractual start date was in September 2005. The draft report began editorial review in
May 2006 and was accepted for publication in February 2007. As the funder, by devising a commissioning
brief, the HTA Programme specified the research question and study design. The authors have been
wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The
HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to
thank the referees for their constructive comments on the draft document. However, they do not accept
liability for damages or losses arising from material published in this report.
The views expressed in this publication are those of the authors and not necessarily those of the 
HTA Programme or the Department of Health.
Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, 
Dr John Powell, Dr Rob Riemsma and Dr Ken Stein
Managing Editors: Sally Bailey and Sarah Llewellyn Lloyd
ISSN 1366-5278
© Queen’s Printer and Controller of HMSO 2007
This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided
that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Applications for commercial reproduction should be addressed to: NCCHTA, Mailpoint 728, Boldrewood, University of Southampton,
Southampton, SO16 7PX, UK.
Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.
Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk. GObjectives: To determine the clinical effectiveness and
cost-effectiveness of (1) alternative strategies for the
prevention of Staphylococcus aureus carriage in patients
on peritoneal dialysis (PD) and (2) alternative 
strategies for the eradication of S. aureus carriage in
patients on PD.
Data sources: Major electronic databases were
searched up to December 2005 (MEDLINE Extra up to
6 January 2006). 
Review methods: Electronic searches were
undertaken to identify published and unpublished
reports of randomised controlled trials and systematic
reviews evaluating the effectiveness of preventing and
treating S. aureus carriage on peritoneal catheter-
related infections. The quality of the included studies
was assessed and data synthesised. Where data were
not sufficient for formal meta-analysis, a qualitative
narrative review looking for consistency between
studies was performed. 
Results: Twenty-two relevant trials were found. These
fell into several groups: the first split is between
prophylactic trials, aiming to prevent carriage, and trials
which aimed to eradicate carriage in those who already
had it; the second split is between antiseptics and
antibiotics; and the third split is between those that
included patients having the catheter inserted before
dialysis started and people already on dialysis. Many of
the trials were small or short-term. The quality was
often not good by today’s standards. The body of
evidence suggested a reduction in exit-site infections,
but this did not seem to lead to a significant reduction
in peritonitis, although to some extent this reflected
insufficient power in the studies and a low incidence of
peritonitis in them. The costs of interventions to
prevent or treat S. aureus carriage are relatively
modest. For example, the annual cost of antibiotic
treatment of S. aureus carriage per identified carrier of
S. aureus was estimated at £179 (£73 screening and
£106 cost of antibiotic). However, without better data
on the effectiveness of the interventions, it is not clear
whether such costs are offset by the cost of treating
infections and averting changes from peritoneal dialysis
to haemodialysis. Although treatment is not expensive,
the lack of convincing evidence of clinical effectiveness
made cost-effectiveness analysis unrewarding at
present. However, consideration was given to the
factors needed in a hypothetical model describing
patient pathways from methods to prevent S. aureus
carriage, its detection and treatment and the detection
and treatment of the consequences of S. aureus (e.g.
catheter infections and peritonitis). Had data been
available, the model would have compared the cost-
effectiveness of alternative interventions from the
perspective of the UK NHS, but as such it helped
identify what future research would be needed to fill
the gaps.
Conclusions: The importance of peritonitis is 
not in doubt. It is the main cause of people having 
to switch from peritoneal dialysis to haemodialysis,
which then leads to reduced quality of life for patients
Health Technology Assessment 2007; Vol. 11: No. 23
iii
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.
Abstract
Systematic review of the effectiveness of preventing and 
treating Staphylococcus aureus carriage in reducing peritoneal
catheter-related infections
K McCormack,1* K Rabindranath,2 M Kilonzo,3 L Vale,1,3 C Fraser,1 L McIntyre,4
S Thomas,4 H Rothnie,4 N Fluck,5 IM Gould6 and N Waugh7
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* Corresponding authorand increased costs to the NHS. Unfortunately, the
present evidence base for the prevention of 
peritonitis is disappointing; it suggests that the
interventions reduce exit-site infections, but not
peritonitis, although this may be due to trials being in
too small numbers for too short periods. Trials are
needed with larger numbers of patients for longer
durations.
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Objectives
The objectives of this review were to determine the
clinical effectiveness and cost-effectiveness of
alternative strategies for the prevention and
eradication of Staphylococcus aureus carriage in
patients on peritoneal dialysis (PD). The aim was to
prevent, or reduce, the frequency of peritonitis. The
review does not cover treatment of peritonitis itself.
Background and intervention
In chronic renal failure, dialysis is used to replace
the kidneys’ function in removing impurities and
unwanted products of metabolism from the blood.
Peritoneal dialysis is a form of ambulatory dialysis
in which fluid is fed into the abdominal cavity via
a catheter through the abdominal wall. The fluid
collects the substances normally excreted by the
kidney. After an interval the fluid is drained out
again. 
The main complication of peritoneal dialysis in
the short term is infection of the peritoneal cavity,
peritonitis. In the longer term, recurrent episodes
of peritonitis can impair diffusion across the
peritoneal membrane, so that peritoneal dialysis is
no longer feasible, which means that patients have
to attend hospital for haemodialysis, usually three
times per week.
One of the organisms which cause peritonitis is
Staphylococcus aureus. It can colonise parts of the
body without symptoms, but may cause infection
where the peritoneal catheter passes through the
skin of the abdomen. These are known as exit-site
infections. It may also contaminate the tip of the
catheter. In both situations, peritonitis may be a
consequence.
Various measures have been used to try to prevent
or eradicate colonisation, in the hope that this will
prevent, or reduce, the frequency of peritonitis.
These include antiseptics and antibiotics. The
antibiotics can be applied locally or given
systemically, by mouth.
S. aureus can develop resistance to commonly used
antibiotics, and is then known as methicillin-
resistant Staphylococcus aureus (MRSA).
Epidemiology
End-stage renal failure can be a consequence of a
number of diseases, the commonest being
glomerulonephritis, diabetes, renal vascular disease,
pyelonephritis and polycystic kidney disease.
Methods
Electronic searches were undertaken to identify
published and unpublished reports of randomised
controlled trials (RCTs) and systematic reviews
evaluating the effectiveness of preventing and
treating S. aureus carriage on peritoneal catheter-
related infections. The main databases searched
were MEDLINE (1966–2005), EMBASE
(1980–2005), CINAHL (1982–2005), BIOSIS
(1985–2005), Science Citation Index (SCI)
(1980–2005), MEDLINE Extra (6 January 2006),
Cochrane Library (Issue 4 2005), Database of
Abstracts of Reviews of Effectiveness (December
2005) and HTA Database (December 2005). The
quality of the included studies was assessed and
data synthesised. Where data were not sufficient
for formal meta-analysis, a qualitative narrative
review looking for consistency between studies was
performed. 
Results
Number and quality of studies and
summary of benefits
Twenty-two trials were found. These fell into
several groups: the first split is between
prophylactic trials, aiming to prevent carriage, and
trials which aimed to eradicate carriage in those
who already had it; the second split is between
antiseptics and antibiotics; and the third split is
between those that included patients having the
catheter inserted before dialysis started and
people already on dialysis. Many of the trials were
small or short-term. The quality was often not
good by today’s standards. The body of evidence
suggested a reduction in exit-site infections but
this did not seem to lead to a significant reduction
in peritonitis, although to some extent this
reflected insufficient power in the studies and a
low incidence of peritonitis in them.
Executive summaryx
Costs
The costs of interventions to prevent or treat
S. aureus carriage are relatively modest. For
example, the annual cost of antibiotic treatment of
S. aureus carriage per identified carrier of S. aureus
was estimated at £179 (£73 screening and £106
cost of antibiotic). However, without better data on
the effectiveness of the interventions, it is not clear
whether such costs are offset by the cost of treating
infections and averting changes from peritoneal
dialysis to haemodialysis.
Cost-effectiveness
Although treatment is not expensive, the lack of
convincing evidence of clinical effectiveness made
cost-effectiveness analysis unrewarding at present.
However, consideration was given to the factors
needed in a hypothetical model describing patient
pathways from methods to prevent S. aureus
carriage, its detection and treatment and the
detection and treatment of the consequences of 
S. aureus (e.g. catheter infections and peritonitis).
Had data been available, the model would 
have compared the cost-effectiveness of 
alternative interventions from the perspective 
of the UK NHS, but as such it helped identify
what future research would be needed to fill 
the gaps.
Conclusions
The importance of peritonitis is not in doubt. It is
the main cause of people having to switch from
peritoneal dialysis to haemodialysis, which leads to
reduced quality of life for patients and increased
costs to the NHS. Unfortunately, the present
evidence base for the prevention of peritonitis is
disappointing; it suggests that the interventions
reduce exit-site infections but not peritonitis,
although this may be due to trials being in too
small numbers for too short periods.
Recommendations for research
The study identified key research questions that
need to be addressed. These are given below.
● What is the natural history of carriage of
S. aureus? What are the links between carriage
and exit-site infection, and between exit-site
infection and peritonitis? What factors predict
carriage?
● Is the problem mainly with MRSA, with
methicillin-sensitive Staphylococcus aureus
(MSSA) being relatively harmless?
● Does decolonisation work, or is recolonisation
rapid?
● Apart from antibiotic and antiseptic use, what
other options for reducing peritonitis are there?
Would more training help?
● Should measures to eradicate carriage be
intermittent or chronic; antiseptics versus
antibiotics?
● Is vaccination worth revisiting?
● Given the common use of mupirocin in renal
units, research into that drug and resistance to
it should be a priority.
Trials are needed with larger numbers of patients
for longer durations.
Executive summaryT
he objectives of this review were to determine
the clinical effectiveness and cost-effectiveness
of alternative strategies for the prevention and
eradication of Staphylococcus aureus carriage in
patients on peritoneal dialysis (PD). The aim was to
prevent, or reduce, the frequency of peritonitis. 
The review does not cover treatment of peritonitis
itself.
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Chapter 1
Objectives of the reviewDescription of the problem
S. aureus is a bacterium that lives completely
harmlessly on the skin and in the nose of about
one-third of normal healthy people. This situation
can be called colonisation or carriage. Other
S. aureus carriage sites include the axillae, vagina,
perineum and occasionally the gastrointestinal
tract.
However, although colonisation of those sites may
not cause any problems there, the presence of the
organism means that more vulnerable parts of the
body may be first contaminated and then infected.
In PD, a catheter is inserted into the abdominal
cavity though the skin of the abdominal wall and
exits through a subcutaneous tunnel. Whenever the
skin is broken, there is a risk of infection. Hence
people on PD are at increased risk because of the
break in the skin. Some may also be at increased
risk of all infections because of the diseases which
lead to renal failure, such as diabetes.
PD is used more in the UK than in other countries.
Almost one-third of the dialysis population in the
UK are on PD1 and 50% of PD patients are known
to be S. aureus carriers.2 Some studies have
reported that nasal carriage of S. aureus is more
frequent in diabetic and immunosuppressed PD
patients.3,4
PD catheter-related infections are an important
cause of morbidity and mortality in the PD
population. Such infections are classified into exit-
site, tunnel infections and peritonitis. An exit-site
infection is defined as purulent drainage at the
catheter exit site with or without erythema. 
A tunnel infection is an infection of the tissues
overlying the subcutaneous portion of the
catheter.5 Peritonitis is inflammation of the
peritoneal membrane. Exit-site or tunnel
infections cause significant morbidity as they can
lead to refractory or recurrent peritonitis.6
Peritonitis is associated with several adverse
consequences. It accounts for the majority of
occasions when the PD catheter has to be
removed, leading to transfer to haemodialysis
(HD).7,8 Peritonitis is one of the most common
causes for hospitalisation in PD patients.9
It contributes to the decline of peritoneal
membrane function, which means that PD may
become impossible. It may also lead to a more
rapid decline in residual renal function (i.e. some
patients still have a little function left in their
kidneys) and is an important predictor of survival.10
Although there can be many different causes of
PD catheter-related infections, S. aureus is an
important cause. It is believed to be the leading
cause of PD catheter exit-site infection11,12 and
one of the most frequent causes of PD-related
peritonitis.13 It has been estimated that the
peritonitis rates due to S. aureus are 0.09–0.22 per
dialysis year.2,14 The cost of S. aureus infections in
the dialysis population in the USA has been
estimated to be over US$200 million annually.15
Several studies have shown a strong link between
S. aureus carriage and PD catheter exit-site and
tunnel infections16–18 and peritonitis.19,20 S. aureus
carriers, have a two- to six-fold higher risk of
S. aureus peritonitis than non-carriers.2,19
Peritonitis due to S. aureus tends to be more severe
than that due to other organisms, with patients
more likely to have fever and hypotension.21
Hospital admission may be prolonged with
S. aureus peritonitis9 and it also increases
mortality.22,23 Furthermore, removal of the PD
catheter is required more often in S. aureus
peritonitis than with peritonitis due to other
bacteria, to resolve the peritonitis or prevent
recurrence.24 Removal of the catheter means that
PD has to be replaced by HD, requiring at least
temporary attendance at hospital dialysis sessions,
usually three times per week.
Descriptions of interventions
Studies comparing carriage and infecting S. aureus
isolates have shown that patients are infected with
their ‘own’ organism, that is, the one they carry on
skin or nose.2,25,26 Although S. aureus is found in
the body in areas other than the nose, elimination
of nasal carriage also leads to loss of carriage in
other sites such as hands and skin,27 implying that
the other parts are being reinfected from the nose.
In addition, the PD catheter exit site is reported to
be most important colonising site of S. aureus
Health Technology Assessment 2007; Vol. 11: No. 23
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Chapter 2
Backgroundstrains that cause peritonitis.28 These important
observations underpin strategies that aim to
reduce S. aureus-related PD catheter infections and
peritonitis.
S. aureus is normally susceptible to a variety of
antibiotics, the most commonly used of which is
mupirocin, given as an ointment. 
Recommendations according to
various guidelines
Various bodies have made recommendations,
although these are not necessarily followed in
practice.
● Renal Association (UK):29 Peritonitis rates
should be less than one episode per 18 patient
months. Mupirocin should be applied to the
exit site either daily or on alternate days. Nasal
carriage of S. aureus should be treated with
mupirocin twice daily for five consecutive days
every 4 weeks. 
● European Renal Association–European Dialysis
and Transplantation Association
(ERA–EDTA):30 Mupirocin should be applied
either at the exit site or intranasally especially
in patients who are S. aureus carriers. 
● International Society of Peritoneal Dialysis:31
Several options are recommended: exit-site
mupirocin daily in all patients or in S. aureus
carriers only or in response to positive S. aureus
culture; intranasal mupirocin every month in
those identified as carriers or only in response
to positive nose culture; exit-site gentamicin in
all patients. 
● Caring for Australians with Renal Impairment
(CARI guidelines):32–34 Prophylactic therapy
using mupirocin ointment, especially for
S. aureus carriage intranasally, is recommended
to decrease the risk of S. aureus catheter exit
site/tunnel infections and peritonitis.
It is clear that although all guidelines recommend
mupirocin for S. aureus nasal carriers, there is
considerable variation with other
recommendations. There has been no systematic
review of evidence for the effectiveness of
interventions for prevention and treatment of
S. aureus carriage in PD patients. It was against
this background that the NHS Research and
Development Programme for Health Technology
Assessment (HTA) commissioned this study. 
Background
4Methods for reviewing
effectiveness
Search strategy
Electronic searches were undertaken to identify
published and unpublished reports of randomised
controlled trials (RCTs) and systematic reviews
evaluating the effectiveness of preventing and
treating S. aureus carriage on peritoneal catheter-
related infections. 
The main databases searched were MEDLINE
(1966–2005), EMBASE (1980–2005), CINAHL
(1982–2005), BIOSIS (1985–2005), Science
Citation Index (SCI) (1980–2005), MEDLINE
Extra (6 January 2006), Cochrane Library (Issue 4
2005), Database of Abstracts of Reviews of
Effectiveness (December 2005) and HTA Database
(December 2005). Searching was restricted to
English language publications only. In addition,
recent conference proceedings, tables of contents
of two key PD journals and reference lists of all
included studies were scanned to identify
additional potentially relevant studies. Full details
of the search strategies used are documented in
Appendix 1.
All titles and abstracts identified in these ways
were assessed to identify potentially eligible
studies. Two reviewers independently assessed
them for inclusion, using a study eligibility form
developed for this purpose (Appendix 2). Any
disagreements were resolved by consensus or
arbitration. Systematic reviews were used to
identify RCTs but were not otherwise included in
this review.
Inclusion and exclusion criteria
Types of studies
All published RCTs and quasi-RCTs (e.g.
allocation by alternation) of patients receiving PD
for end-stage renal disease in whom alternative
interventions were compared for the prevention
and treatment of S. aureus carriage were included.
For the purposes of this review, studies comparing
alternative interventions for the treatment of
clinical infections and studies which did not
report outcomes separately for S. aureus were
excluded. 
Types of participants
The trials included patients on PD for end-stage
renal disease from any cause.
Types of outcomes
The following measures of outcomes were sought:
Primary outcome:
1. number of patients with peritonitis caused by
S. aureus.
Secondary outcomes:
1. number of patients with S. aureus carriage
2. time to S. aureus carriage
3. peritonitis rate (number of episodes over total
patient months on PD) caused by S. aureus
4. time to first peritonitis episode caused by
S. aureus
5. peritonitis relapse (number and specify time
to) caused by S. aureus
6. number of patients requiring catheter removal
caused by S. aureus
7. number of patients switching to HD caused by
S. aureus
8. number of patients requiring catheter
replacement caused by S. aureus
9. number of patients with exit-site and/or
tunnel infections caused by S. aureus
10. exit-site and/or tunnel infection rate caused by
S. aureus
11. side-effects
12. death due to peritonitis caused by S. aureus
13. hospitalisation rates
14. quality of life
15. development of antibiotic resistance.
Data extraction strategy
The titles and abstracts of all papers identified by
the search strategy were screened. Full text copies
of all potentially relevant studies were obtained
and assessed for inclusion. Reviewers were not
blinded to the names of studies’ authors,
institutions or sources of the reports. Any
disagreements were resolved by consensus or
arbitration. 
A data extraction form was developed to record
details of trial methods, participants, interventions,
patient characteristics and outcomes (Appendix 3).
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Chapter 3
Efficacy and safetyTwo reviewers independently extracted data from
the included studies. Any differences that could
not be resolved through discussion were referred
to an arbiter. 
Quality assessment strategy
Two reviewers, working independently, assessed
the methodological quality of the included studies.
Again, any disagreements were resolved by
consensus or arbitration. The system for classifying
methodological quality of controlled trials was
based on an assessment of four principal potential
sources of bias: selection bias caused by inadequate
concealment of allocation of treatments; attrition
bias caused by losses to follow-up without
appropriate intention-to-treat (ITT) analysis;
detection bias caused by biased ascertainment of
outcome where knowledge of the allocation might
have influenced the measurement of outcome; and
selection bias in analysis (Appendix 3).
Data synthesis
For trials with multiple publications, only the most
up-to-date data for each outcome were included.
Dichotomous outcome data were combined using
the Mantel–Haenszel relative risk (RR) method
and 95% confidence intervals (CIs) and p-values
were calculated for the estimates. The results were
all reported using a fixed-effects model. 2 tests
and I2 statistics were used to explore statistical
heterogeneity across studies and, when present,
random effects methods were applied. Other
possible reasons for heterogeneity were explored
using sensitivity analyses. The meta-analyses were
conducted using the standard Cochrane software
RevMan 4.2. 
Where data were not sufficient for formal meta-
analysis, a qualitative narrative review looking for
consistency between studies was performed. 
Results
Quantity and quality of research
available
Number of studies identified
The results of the searches are summarised in
Table 1. The numbers retrieved from the searches
in CINAHL, SCI, Biosis and CENTRAL and
screening of full text journals include only the
additional reports found after excluding those
identified from the MEDLINE/EMBASE multifile
search.
A total of 498 titles and abstracts were identified
from the various searches, of which 394 were
clearly outwith the scope of this review. The
remaining 104 reports (90 full text papers and 14
abstracts) were selected for full assessment. Table 2
details the numbers of these that were included
and excluded. 
Number and type of studies included
Twenty-five reports (21 full text papers and four
abstracts) describing 22 RCTs met the inclusion
criteria for the review and were included in the
review of clinical effectiveness. The majority of
these reports were identified from the
MEDLINE/EMBASE search (20), with two each
identified from SCI and the full text journals and
one from BIOSIS. The list of included studies and
associated references are listed in Appendix 4. No
studies were identified only from CINAHL.
Trials fell into several groups. The first split is
between prophylactic trials, aiming to prevent
Efficacy and safety
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TABLE 1 Search results
Database No. retrieved
MEDLINE/EMBASE/MEDLINE Extra 381
multifile search (after deduplication 
in Ovid)
CINAHL 23
SCI 56
BIOSIS 12
CENTRAL 2
CDSR 1
DARE 7
HTA database 2
NRR 1
CCT 0
Clinical Trials 0
SCI Proceedings 2
Selected from conference abstracts 2
Selected from full text journals 9
Total 498
TABLE 2 Papers selected for full assessment
Assessment No. of papers
Included in review 25
Systematic reviews  7
Retained for background information 26
Excluded – not RCTs 17
Excluded – treatment of clinical  7
infections
Excluded – outcomes not reported  22
separately for S. aureus carriage
Unobtainable papers 0
Total 104carriage, and between trials which aimed to
eradicate carriage in those who already had it.
The second split is between antiseptics and
antibiotics. The third split is between those that
included patients having the catheter inserted
before dialysis started and those where the people
were already on dialysis. 
Number and type of studies excluded, with
reasons for specific exclusions
A total of 46 reports were obtained but
subsequently were excluded because they failed to
meet one or more of the inclusion criterion. Of
these, 17 were not RCTs, seven were concerning
the treatment of clinical infections and in 22 the
authors did not report outcomes separately for
participants with S. aureus carriage (18 primary
reports and four secondary reports).
Study quality, characteristics and evidence rating
A summary of the quality assessment of the 22
RCTs is presented in Table 3 and the detailed
quality assessment for each of the included studies
is reported in Appendix 5. The method of
randomisation used was stated explicitly for 11 of
22 trials: a central randomisation service was used
in one study, consecutively numbered, sealed
envelopes were used in one study, computer-
generated random numbers were used in one
study, there was consecutive allocation in two, by
random numbers table in three, by date of follow-
up in one, assigned by a third party in one and
random selection by cards in one. By modern
standards, most of these methods are unsatisfactory,
but some of the trials were done some time ago. In
11 trials, the allocation was said to be
‘randomised’ but the method was not specified.
Concealment of allocation was adequate in only
one trial, suboptimal in four and unclear in 17. 
In the majority of trials, it was unclear whether
studies blinded the care provider, participant,
outcome assessor or data analyst (but it is
questionable if this is possible given the nature of
the treatments compared). Five studies included
an ITT analysis but it was unclear if this were the
case for the remaining 25 studies. 
Eligibility criteria were clearly specified in 21
studies. The mean or median duration of follow-
up ranged from at least 48 hours to 1 year. This
was not reported for three studies.
Characteristics of included studies
The comparisons made and characteristics of the
RCTs are summarised in Table 4 and a detailed
description for each of the included studies is
reported in Appendix 6. Within the 22 eligible
RCTs, there were 30 relevant comparisons (four
trials had three arms). Three trials took place in
the UK, eight in the USA, two in Hong Kong, two
in Brazil and one each in Spain, Turkey, Singapore
and Canada. There were two multi-centre
European trials and one multi-centre Australia
and New Zealand trial. Across the trials
recruitment dates ranged from May 1987 to
August 2003. Eleven trials failed to provide
information on recruitment dates. The number of
participants randomised ranged from 15 to 267.
Two trials had more than 200 participants, eight
more than 100 participants and 12 fewer than 100
participants. Eighteen trials gave details of the
numbers of men and women in each trial group.
Seventeen trials gave details of participants’ ages.
One trial included children only.
Assessment of effectiveness
Table 5 gives a summary of the outcomes reported
in the included studies. 
Prophylaxis amongst all patients
Eighteen trials evaluated prophylaxis amongst all
patients regardless of their S. aureus status at trial
entry. Four trials evaluated prophylaxis at the time
of catheter insertion and the remaining trials
considered prophylaxis given once dialysis had
commenced. Five trials compared antibiotic
treatment with no antibiotic treatment, four trials
compared two different antibiotic regimes, one
three-armed trial compared two different
antibiotic regimes with no antibiotic treatment,
three trials compared antiseptic treatment with no
antiseptic treatment, one trial compared two
different types of antiseptics, one trial compared a
vaccination with combined staphylococcus
Health Technology Assessment 2007; Vol. 11: No. 23
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TABLE 3 Summary of the quality assessment of the included RCTs
Allocation  Blinding of  Blinding of  Blinding of  Blinding of  ITT Lost to 
concealment investigators participants assessor data analysis follow-up
Adequate: 1 Yes: 1 Yes: 2 Yes: 1 Yes: 0 Stated: 3 Yes: 12
Inadequate: 4 No: 5 No: 4 No: 2 No: 1 Not stated: 19 No: 0
Unclear: 17 Unclear: 17 Unclear: 16 Unclear: 19 Unclear: 21 Unclear: 10Efficacy and safety
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TABLE 4 Summary of the comparisons made and baseline characteristics
Study Comparison No. of  Age (years)a Male/female
participants
Prophylaxis amongst all patients
Antibiotic versus no antibiotic
Catheter insertion:
Bennett-Jones, 198835 I.v. gentamicin  13 52.7 ± 18.6b 8/5
No treatment 13 52.7 ± 18.6b 9/4
Lye, 199236 I.v. cefazolin and gentamicin  25 56.0 ± 14.3 8/17
No treatment 25 52.3 ± 14.0 15/10
During dialysis:
Sharma, 197137 Neomycin by mouth or nasogastric tube  48 dialysates – –
Placebo 41 dialysates – –
Wong, 200338 Mupirocin ointment 78 (73 analysed) 60 ± 12c 32/41
No treatment 88 (81 analysed) 59 ± 13c 47/34
Zimmerman, 199139 Rifampin 32 53 ± 3 17/15
No treatment 32 55 ± 4 24/8
Antibiotic versus antibiotic
During dialysis:
Bernardini, 199640 Mupirocin ointment 41 – 49%/51%
Oral rifampin 41 – 59%/41%
Bernardini, 200541,42 Mupirocin ointment 66 51 ± 15 38/28
Gentamicin ointment 67 51 ± 15 34/33
Cavdar, 200443 Mupirocin ointment applied once weekly  18 55.3 ± 1.8c 10/8
Mupirocin ointment applied thrice weekly 18 55.0 ± 2.3c 11/7
Antibiotic versus antibiotic versus no antibiotic
Catheter insertion:
Gadallah, 200044,45 I.v. vancomycin 90 (103 procedures) 46 (15 to 72)b 38/52
I.v. cefazolin 88 (102 procedures) 47 (20 to 81)b 43/45
No treatment 87 (100 procedures) 45 (19 to 76)b 38/49
Antiseptic versus no antiseptic
Catheter insertion:
Waite, 199746 Povidone–iodine ointment 61 54.4 ± 15.1 33/28
No treatment 56 53.2 ± 14.5 30/26
During dialysis:
Luzar, 19903 Povidone–iodine 74 – 63%/37%
Non-disinfectant soap 53 – 59%/41%
Sesso, 198847 Chlorhexidine 20 – –
Neutral soap 19 – –
Wilson, 199748 Povidone–iodine spray 77 catheters 53 (18–82)e 55/22
No treatment 72 catheters 51 (21–76)e 43/29
Wong, 200249 Chlorhexidine liquid soap 69 59.0 ± 11.50b 34/35
Pure liquid soap 48 56.3 ± 11.7b 23/25
Antiseptic versus antiseptic
During dialysis:
Fuchs, 199050 Chlorhexidine 18 46c 7/11
Sodium hypochlorite 13 47c 7/6
Povidone–iodine swabsticks plus  20 55c 13/7
povidone ointment
Other
During dialysis:
Poole-Warren, 199151 Vaccination 65 54 ± 11 1.5 (ratio)
Placebo 59 52 ± 14 0.7 (ratio)
continuedtoxoid/whole killed staphylococci formulation with
a placebo, one three-armed trial compared a
catheter immobiliser with the use of tape and non-
immobilisation and one trial compared the ‘flush
before fill’ technique with standard practice.
Table 6 provides details, where reported, of the
results for the following outcomes: number of
patients with S. aureus carriage (at trial entry);
number of patients with peritonitis; peritonitis
rate (number of episodes over total patient
months on PD); number of patients requiring
catheter removal; number of patients with exit-site
and/or tunnel infections; and the exit-site and/or
tunnel infection rate.
Time to S. aureus carriage
One trial, comparing vaccination with a combined
staphylococcus toxoid/whole killed staphylococci
formulation (SB) given intramuscularly with
placebo,51 also reported the number of S. aureus-
positive nasal swabs relative to the total nasal
swabs taken at each time point (Table 7). 
Time to the first peritonitis episode
One trial comparing intravenous vancomycin
approximately 12 hours before catheter placement
with intravenous cefazolin approximately 3 hours
before catheter placement with no antibiotics for
at least 1 week before procedure, reported the
time to the first peritonitis episode.44 There was
one case of peritonitis at 6 days in the intravenous
cefazolin and two cases of peritonitis at 1 and
4 days in the group allocated to receive no
antibiotics at least 1 week before surgery. 
Side-effects
Three trials reported side-effects of antibiotic
prophylaxis: Bernardini and colleagues40 reported
that four out of 41 patients experienced nausea
and vomiting in the oral rifampin group and one
other required liver function tests. There were no
reported side-effects in the mupirocin group.
Bernardini and colleagues41 reported exit-site
irritation in seven out of 66 patients in the
mupirocin group and seven out of 67 patients in
the gentamicin group. Wilson and colleagues48
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TABLE 4 Summary of the comparisons made and baseline characteristics (cont’d)
Study Comparison No. of  Age (years)a Male/female
participants
Turner, 199252 Catheter immobiliser 22 45 ± 15.51 –
Tape 23 40 ± 14.26 –
Non-immobilisation 21 43  ± 15.8 –
Warady, 200353 ‘Flush before fill’  62 11.4 ± 5.6d 54.8%/45.2%
Flushing with 15 ml of sterile dialysate  59 11.2 ± 6.0d 59.3%/40.7%
Treatment of S. aureus carriage
Antibiotic versus no antibiotic
During dialysis:
Blowey, 199454 Oral rifampin plus bacitracin 7 –
No treatment 8 –
Mupirocin Study  Mupirocin ointment 134 60.3c 60.4%/39.6%
Group, 199655,56 Placebo ointment 133 60.3c 60.2%/39.8%
Antibiotic versus antibiotic
During dialysis:
Perez-Fontan, 199257 Mupirocin nasal ointment 12 51 ± 15b 5/7
Neomycin sulphate ointment 10 48 ± 21b 5/5
Antibiotic versus antibiotic versus no antibiotic
During dialysis:
Sesso, 199458 Sodium fusidate ointment 9 46.1 ± 3.8 (33–69)e 6/3
Oral ofloxacin 9 36.6 ± 4.6 (22–61)e 6/3
Placebo tablets 13 42.1 ± 4.6 (17–68)e 9/4
a Data are expressed as mean ± standard deviation (SD) unless stated otherwise.
b Measure unclear.
c Mean.
d Mean ± standard error of the mean (SEM).
e Mean ± standard error (range).Efficacy and safety
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.reported a rash and pruritus at the catheter exit
site in five patients allocated to use the
povidone–iodine spray. There were no reported
side-effects in the group which received no
treatment. 
Death due to peritonitis caused by S. aureus
Only one trial reported this outcome.37 This trial
compared neomycin 0.5 g by mouth or nasogastric
tube every 6 hours with a placebo and reported
that there were no deaths due to peritonitis caused
by S. aureus.
Development of antibiotic resistance 
One trial43 comparing mupirocin applied to the
exit site once weekly with mupirocin applied three
times weekly reported no difference between the
groups (one out of seven isolations were resistant
to mupirocin in the group applying mupirocin
once weekly and one isolation resistant to
mupirocin and methicillin in the group applying
mupirocin three times weekly).
No data were reported for the following outcomes:
peritonitis relapse, number of patients requiring
catheter replacement, hospitalisation rates and
quality of life.
Oral antibiotics versus no antibiotics
Four trials compared an oral antibiotic with no
antibiotics and one trial compared two different
types of oral antibiotics with no antibiotic. When
considering all oral antibiotics together, there were
fewer cases of peritonitis caused by S. aureus in the
groups which received antibiotics (Figure 1: 6/283
versus 7/185: RR 0.69, 95% CI 0.28 to 1.72;
p = 0.43), but this was not a statistically significant
difference. There were also fewer cases of exit-site
and/or tunnel infections caused by S. aureus
(Figure 2, 5/70 versus 20/70: RR 0.27, 95% CI 0.11
to 0.65; p = 0.003). The direction of effect was
similar when considering subcategories (catheter
insertion and during dialysis).
Topical antibiotics versus no antibiotics
Only one trial38 compared the use of a topical
antibiotic with no antibiotics. There was no
difference in the number of patients with
peritonitis caused by S. aureus. However, there
were 0/78 cases of exit-site and/or tunnel
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TABLE 7 S. aureus nasal carriage versus weeks following
vaccination, expressed as number of carriers/group total51
No. of weeks Vaccination Placebo
Pre-study 13/40 11/36
7 19/50 14/44
19 11/51 14/46
32 9/29 5/20
44 2/22 6/25
57 10/20 6/22
Study
or subcategory
01 Catheter insertion
 Gadallah  2000
 Lye  1992
Subtotal (95% CI)
Total events: 3 (Antibiotic), 2 (No antibiotic)
Test for heterogeneity: 2 = 2.45, df = 1 (p = 0.12), I2 = 59.2%
Test for overall effect: z = 0.01 (p = 0.99)
02 During dialysis
 Sharma  1971
 Zimmerman  1991
Subtotal (95% CI)
Total events: 3 (Antibiotic), 5 (No antibiotic)
Test for heterogeneity: 2 = 1.09, df = 1 (p = 0.30), I2 = 8.3%
Test for overall effect: z = 0.76 (p = 0.45)
Total (95% CI)
Total events: 6 (Antibiotic), 7 (No antibiotic)
Test for heterogeneity: 2 = 3.46, df = 3 (p = 0.33), I2 = 13.2%
Test for overall effect: z = 0.60 (p = 0.55)
   1/178
 2/25
      203
 0/48
 3/32
    80
283
 2/87
 0/25
     112
 2/41
 3/32
    73
185
30.26
5.63
35.89
30.32
33.79
64.11
100.00
0.24 (0.02 to 2.66)
5.00 (0.25 to 99.16)
0.99 (0.23 to 4.23)
0.17 (0.01 to 3.47)
1.00 (0.22 to 4.59)
0.61 (0.17 to 2.18)
0.75 (0.29 to 1.93)
2000
1992
1971
1991
0
0
0
0
Antibiotic
n/N
No antibiotic
n/N
RR (fixed)
95% CI
RR (fixed)
95% CI
Year Order Weight
%
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
FIGURE 1 Oral antibiotic prophylaxis amongst all patients: number of patients with peritonitis caused by S. aureusinfections in the group allocated to use a topical
antibiotic compared with 10/88 cases in the no
treatment group [five of which were methicillin-
resistant Staphylococcus aureus (MRSA) and five
were methicillin-sensitive Staphylococcus aureus
(MSSA)]. 
Antiseptic versus no antiseptic
When considering all antiseptics together, there
were more cases of peritonitis caused by S. aureus
in the groups allocated to antiseptic use (Figure 3:
16/231 versus 12/197: RR 1.08, 95% CI 0.54 to 2.16;
p = 0.84), but this was not statistically significant.
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Study
or subcategory
01 Catheter insertion
 Bennett-Jones  1988
 Lye  1992
Subtotal (95% CI)
Total events: 2 (Antibiotic), 8 (No antibiotic)
Test for heterogeneity: 2 = 0.88, df = 1 (p = 0.35), I2 = 0%
Test for overall effect: z = 1.78 (p = 0.07)
02 During dialysis
 Zimmerman  1991
Subtotal (95% CI)
Total events: 3 (Antibiotic), 12 (No antibiotic)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.33 (p = 0.02)
Total (95% CI)
Total events: 5 (Antibiotic), 20 (No antibiotic)
Test for heterogeneity: 2 = 0.97, df = 2 (p = 0.62), I2 = 0%
Test for overall effect: z = 2.93 (p = 0.003)
 0/13
 2/25
    38
 3/32
    32
70
 4/13
 4/25
    38
12/32
     32
70
21.95
19.51
41.46
58.54
58.54
100.00
0.11 (0.01 to 1.88)
0.50 (0.10 to 2.49)
0.29 (0.08 to 1.13)
0.25 (0.08 to 0.80)
0.25 (0.08 to 0.80)
0.27 (0.11 to 0.65)
1988
1992
1991
0
0
0
Antibiotic
n/N
No antibiotic
n/N
RR (fixed)
95% CI
RR (fixed)
95% CI
Year Order Weight
%
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
FIGURE 2 Oral antibiotic prophylaxis amongst all patients: number of patients with exit-site and/or tunnel infections caused by S.
aureus
Study
or subcategory
01 Catheter insertion
 Waite  1997
Subtotal (95% CI)
Total events: 0 (Antiseptic), 2 (No antiseptic)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.10 (p = 0.27)
02 During dialysis
 Luzar  1990
 Sesso  1988
 Wilson  1997
Subtotal (95% CI)
Total events: 16 (Antiseptic), 10 (No antiseptic)
Test for heterogeneity: 2 = 1.02, df = 2 (p = 0.60), I2 = 0%
Test for overall effect: z = 0.67 (p = 0.50)
Total (95% CI)
Total events: 16 (Antiseptic), 12 (No antiseptic)
Test for heterogeneity: 2 = 2.55, df = 3 (p = 0.47), I2 = 0%
Test for overall effect: z = 0.21 (p = 0.84)
 0/61
    61
 8/74
 6/19
 2/77
      170
231
 2/56
    56
 3/53
 4/16
 3/72
      141
197
19.23
19.23
25.81
32.06
22.89
80.77
100.00
0.18 (0.01 to 3.75)
0.18 (0.01 to 3.75)
1.91 (0.53 to 6.86)
1.26 (0.43 to 3.71)
0.62 (0.11 to 3.62)
1.29 (0.61 to 2.70)
1.08 (0.54 to 2.16)
Antiseptic
n/N
No antiseptic
n/N
RR (fixed)
95% CI
RR (fixed)
95% CI
Weight
%
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
FIGURE 3 Antiseptic prophylaxis amongst all patients: number of patients with peritonitis caused by S. aureusHowever, when considering antiseptic use at the
time of catheter insertion, there were fewer cases
of peritonitis (one trial). There were fewer cases of
exit-site and/or tunnel infections caused by
S. aureus in the groups allocated to antiseptic use
(Figure 4, 26/281 versus 50/229: RR 0.43, 95% CI
0.28 to 0.66; p = 0.0001). The direction of effect
was similar when considering subcategories
(catheter insertion and during dialysis).
Treatment of S. aureus carriage
Four trials evaluated treatment of S. aureus
carriage, all during dialysis. Two compared
antibiotic treatment with no antibiotic treatment,
one trial compared two different antibiotic regimes
and one three-armed trial compared two different
antibiotic regimes with no antibiotic treatment.
Table 8 provides details, where reported, of the
results for the following outcomes: number of
patients with S. aureus carriage; number of patients
with peritonitis; peritonitis rate (number of
episodes over total patient months on PD); number
of patients requiring catheter removal; number of
patients with exit-site and/or tunnel infections;
and the exit-site and/or tunnel infection rate.
Time to S. aureus carriage
One trial57 reported time to recolonisation after
initial treatment and the results are presented in
Table 9. 
Side-effects
Two trials reported side-effects: the Mupirocin
Study Group55 reported six episodes of side-effects
in six patients (one withdrew due to rhinitis) using
mupirocin ointment and eight episodes in seven
patients (one withdrew due to rhinorrhea and
sneezing) using the placebo ointment; and Sesso
and colleagues58 reported that one patient using
sodium fusidate ointment discontinued use due to
nasal irritation.
Death due to peritonitis caused by S. aureus
One trial reporting this outcome58 reported that
there were no deaths due to peritonitis caused by
S. aureus.
Development of antibiotic resistance
One trial58 reported that no patient developed
ofloxacin-resistant organisms.
There were no data reported for the following
outcomes: time to first peritonitis episode;
peritonitis relapse; number of patients requiring
catheter replacement; hospitalisation rates; and
quality of life.
Oral antibiotics versus no antibiotics
Two trials compared oral antibiotics with no
antibiotics. When considering all oral antibiotics
together, there were fewer cases of peritonitis
caused by S. aureus in the groups which received
Health Technology Assessment 2007; Vol. 11: No. 23
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Study
or subcategory
01 Catheter insertion
 Waite  1997
Subtotal (95% CI)
Total events: 2 (Antiseptic), 8 (No antiseptic)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.91 (p = 0.06)
02 During dialysis
 Luzar  1990
 Wilson  1997
 Wong  2002
Subtotal (95% CI)
Total events: 24 (Antiseptic), 42 (No antiseptic)
Test for heterogeneity: 2 = 3.16, df = 2 (p = 0.21), I2 = 36.7%
Test for overall effect: z = 3.36 (p = 0.0008)
Total (95% CI)
Total events: 26 (Antiseptic), 50 (No antiseptic)
Test for heterogeneity: 2 = 4.18, df = 3 (p = 0.24), I2 = 28.2%
Test for overall effect: z = 3.87 (p = 0.0001)
 2/61
    61
15/74
  9/77
  0/69
       220
281
 8/56
    56
16/53
22/72
  4/48
       173
229
15.16
15.16
33.89
41.33
9.62
84.84
100.00
0.23 (0.05 to 1.04)
0.23 (0.05 to 1.04)
0.67 (0.36 to 1.24)
0.38 (0.19 to 0.77)
0.08 (0.00 to 1.41)
0.46 (0.30 to 0.78)
0.43 (0.28 to 0.66)
Antiseptic
n/N
No antiseptic
n/N
RR (fixed)
95% CI
RR (fixed)
95% CI
Weight
%
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
FIGURE 4 Antiseptic prophylaxis amongst all patients: number of patients with exit-site and/or tunnel infections caused by S. aureusEfficacy and safety
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–antibiotics (Figure 5: 1/16 versus 7/21: RR 0.27,
95% CI 0.05 to 1.35; p = 0.11) and fewer cases of
exit site and/or tunnel infections caused by S. aureus
(Figure 6, 2/16 versus 5/21: RR 0.60, 95% CI 0.16
to 2.28; p = 0.46). However, these results were not
statistically significant.
Topical antibiotics versus no antibiotics
Two trials compared topical antibiotics with no
antibiotics. When considering all topical antibiotics
together, there were fewer cases of peritonitis
caused by S. aureus in the groups which received
antibiotics (Figure 7: 22/143 versus 29/146: RR 0.80,
95% CI 0.49 to 1.32; p = 0.39), fewer patients
requiring catheter removal (Figure 8, 7/143 versus
11/142: RR 0.63, 95% CI 0.29 to 1.39; p = 0.26),
and fewer cases of exit site and/or tunnel infections
caused by S. aureus (Figure 9, 14/143 versus 23/146:
RR 0.66, 95% CI 0.36 to 1.20; p = 0.17). However,
these results were not statistically significant. 
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FIGURE 5 Treatment of S. aureus carriage with oral antibiotics: number of patients with peritonitis caused by S. aureus
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FIGURE 7 Treatment of S. aureus carriage with topical antibiotics: number of patients with peritonitis caused by S. aureus
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FIGURE 6 Treatment of S. aureus carriage with oral antibiotics: number of patients with exit-site and/or tunnel infections caused by
S. aureusEfficacy and safety
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FIGURE 8 Treatment of S. aureus carriage with topical antibiotics: number of patients requiring catheter removal
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FIGURE 9 Treatment of S. aureus carriage with topical antibiotics: number of patients with exit-site and/or tunnel infections caused
by S. aureus
TABLE 10 Summary of the clinical effect size
Outcome Prophylaxis amongst all  Treatment of S. aureus carriage
n/N RR (95% CI) n/N RR (95% CI)
Oral antibiotic versus no antibiotic
Peritonitis (no.) 6/283 vs 7/185  0.75 (0.29 to 1.93) 1/16 vs 7/21 0.27 (0.05 to 1.35)
ESI and/or TI (no.) (5/70 vs 20/70) 0.27 (0.11 to 0.65) 2/16 vs 5/21 0.60 (0.16 to 2.28)
Topical antibiotic versus no antibiotic
Peritonitis (no.) ND ND 22/143 vs 29/146 0.80 (0.49 to 1.32)
Catheter removal (no.) ND ND 7/143 vs 11/142 0.63 (0.29 to 1.39)
ESI and/or TI (no.) ND ND 14/143 vs 23/146 0.66 (0.36 to 1.20)
Antiseptic versus no antiseptic
Peritonitis (no.) 16/231 vs 12/197 1.08 (0.54 to 2.16) ND ND
ESI and/or TI (no.) 26/281 vs 50/229 0.43 (0.28 to 0.66) ND ND
ND, no data.Clinical effect size
When considering trials comparing antibiotics
with no antibiotics, a summary of the clinical effect
size for all outcomes where data were available are
given in Table 10. 
When considering prophylaxis amongst all
patients, there is a consistent finding that exit-site
and/or tunnel infections are statistically
significantly reduced with the use of antibiotics
(oral or topical) and antiseptics. However, these
findings do not appear to translate into a
reduction in peritonitis. To some extent this may
reflect the greater frequency of exit-site and/or
tunnel infections than peritonitis, and hence lower
power for peritonitis, but it does raise the question
of how carriage leads to peritonitis.
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In this chapter, the approach taken to consider the
relative cost-effectiveness of interventions to
prevent and treat S. aureus carriage is presented. 
A review of previous economic evaluations has not
been conducted but one economic evaluation
conducted alongside an RCT was identified.59
This economic evaluation compared prophylactic
nasel mupirocin with placebo in patients either
starting or established on continuous ambulatory
PD. Although this study was generally well
conducted and reported, it did not consider the
full range of interventions for the prevention and
treatment of S. aureus carriage. As reported in
Table 8, the use of the antibiotics reduced the rate
of a catheter infection caused by S. aureus from
one every 28.1 months to one every 99.3 months.
The incremental cost per S. aureus-related catheter
infection prevented in 1994 prices was £187. The
costs included the cost of screening and
prophylaxis for 1 year and the cost savings arising
from the reduced use of therapeutic antibiotics
and hospitalisations avoided. Quality-adjusted life-
years (QALYs) were not reported as part of this
study. Nevertheless, the gain in QALYs required to
provide an incremental cost per QALY that society
might consider worthwhile (between £20,000 and
£30,000 per QALY) would be between 0.0019 and
0.0029. This would be equivalent to between an
additional 0.7–1.1 days in full health over 1 year
(1 day in full health is equal to 0.00274 QALYs).
From this particular study, a judgement would be
required as to whether the gains in QALYs
estimated could be realised in practice and, even if
they can be realised, whether society would be
willing to pay for these additional benefits. 
The usefulness of the study by Davey and
colleagues59 is that the results indicate that it is
not implausible that interventions to prevent or
treat S. aureus carriage might be cost-effective.
Ideally, an economic evaluation comparing all
relevant interventions (including the use of a no
treatment arm) and utilising the best available
evidence would be performed. 
The first part of this chapter outlines the
framework provided by economic evaluation for
informing decision-making. As described in this
section, there is insufficient evidence to determine
the relative efficiency of the alternative
interventions. In response to the limited evidence
available, no economic evaluation was performed.
However, a hypothetical model is outlined. If
sufficient data were available from future research
to populate this model, then it would provide an
explicit framework to estimate cost-effectiveness. 
The economic approach
Relationship between benefits and cost
The objective of economic evaluation is to provide
information to assist decision-makers in the
allocation of available scarce resources so that
benefits can be maximised. The decision to use
resources in one way means that the opportunity
to use them in other desirable ways is given up.
The cost of this decision is the benefits (health
gains, etc.) that could have been obtained had the
resources been used in another way. The
‘opportunity cost’ of a decision to use resources in
one way is equivalent to the benefits forgone in
the best alternative use of these resources. One of
the goals of healthcare decision-making is to
maximise benefits and minimise opportunity costs.
To achieve this, information is required on both
resource use (i.e. costs) and benefits (i.e.
effectiveness) from alternative courses of action. 
Data on effectiveness and costs can be brought
together in a matrix format (Figure 10) to aid in
the judgement about whether a new procedure is
preferable to a comparator. In Figure 10, it can be
seen that, relative to a comparator, the new
procedure could achieve (1) greater effectiveness,
(2) the same level of effectiveness or (3) less
effectiveness. Of course, a fourth option is possible
whereby there is not enough evidence to make a
judgement on whether the new procedure is more
or less effective. In terms of cost, a new procedure
could (A) be less costly, (B) result in no difference
in costs or (C) be more costly (again, there is the
possibility of there being not enough evidence to
judge, as represented by row D). 
Figure 10 is adapted from that which appeared in
early editions of the Cochrane Collaboration
Handbook. For any procedure to prevent or treat
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Chapter 4
Economic evaluationS. aureus carriage or infection, the optimum
position on the matrix is square A1, where an
experimental treatment would both save costs and
have greater effectiveness relative to current
treatment. In squares A1, A2 and B1, the new
procedure is more efficient and is assigned a ✓
response to the question of whether it is to be
preferred to current practice. In squares B3, C2,
and C3 the new procedure is less efficient and
thus receives a ✕ response. In squares A3 and C1,
a judgement would be required as to whether the
more costly procedure is worthwhile in terms of
the additional effectiveness gained. Square B2 is
neutral, as there is no difference in either costs or
effectiveness and other reasons may be needed to
justify the adoption of treatment. The areas
marked with a ? response represent situations in
which there is not enough evidence on
effectiveness, costs or both to judge whether the
new procedure is to be preferred.
Consideration of the available evidence
As reported in Chapter 3, the evidence available
on relative effectiveness of the alternative methods
of preventing or treating S. aureus carriage as a
means of preventing peritonitis was limited. In
terms of the matrix set out in Figure 10 there is
insufficient evidence to draw any conclusions
about relative effectiveness (column 4 of the
matrix), and hence about the relative cost-
effectiveness of any of the interventions (square
D4 of the matrix). Additional data collection is
required to conduct a formal economic evaluation.
The structure for a hypothetical economic model
is presented in the next section. 
Hypothetical economic model
The methods for a model and its use are
illustrated below, and this helps to highlight the
areas where additional data would be required
before a robust evaluation could be conducted. A
Markov model is used to display the temporal and
logical sequence of prevention and treatment
events. This approach adopted as a Markov model
has the ability to represent repetitive events, and
the time dependence of both probabilities and
utilities which allows for more accurate
representation of clinical settings that involve
these issues.60 The model would be designed to
estimate costs from the UK NHS perspective and
outcomes in terms of QALYs. 
This study focuses on patients who receive PD as
the initial modality of treatment. A patient who
elects or receives PD could over time either die,
receive a transplant or transfer to HD. The
hypothetical model does not include
transplantation and hence may be considered
applicable to the majority of patients who, for
whatever reason (usually lack of donor organs), do
not receive a transplant. As part of the process of
developing the model, the parameters needed to
assess the cost-effectiveness of alternative
interventions were identified. The systematic
review of effectiveness reported in Chapter 3,
secondary data sources and consultation with
clinical experts would provide the parameter
estimates. Where such data were likely to be
deficient, this has been indicated in the text, to aid
future research. The model structure was based on
Economic evaluation
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Effectiveness
decreasing
Cost
increasing
✓✓ ?
✓✓  ✕✕ ?
✕✕ ?
????
1234
A
B
C
D
  ✓  = recommended experimental treatment
  ✕  = recommended control
✓ ✕ = neutral
  = judgement required
   ?  = not enough evidence
Compared with control treatment, 
experimental treatment is:
1. more  effective
2.  of equal effectiveness
3. less  effective
4.  insufficient evidence to judge
A. less  costly
B.  of equal cost
C. more costly
D. insufficient evidence to judge
FIGURE 10 Matrix combining costs and effectivenessdetailed discussions with clinical members of the
review team about the care pathways that patients
might follow while on PD and further discussion
about how these pathways (and transitions
between different modalities of treatment and
clinical events) would be influenced by the
prevention or treatment of S. aureus carriage. The
model was then presented to the clinicians and
other members of the review team and any
relevant changes made to the structure.
Description of the model
The model is made up of a set of health states
between which a patient can move over specified
periods of time (Figure 11). On entry into the
model, all patients receive PD. The patient will
spend 4 weeks in each state (the cycle length)
before facing the possibility of making a transition
to another state. 
Within the model patients could move into any
one of the following states: 
1. ‘Catheter insertion’. In this initial state a patient
has their peritoneal catheter inserted and
begins PD. At the time of their peritoneal
catheter insertion the patient may receive a
prophylactic intervention or a treatment of 
S. aureus carriage. Following the first 4 weeks
after insertion of the catheter, a patient may
remain on PD with or without carriage of 
S. aureus. Patients in this state could potentially
also develop an infection, transfer to HD or die.
2. ‘On PD without SA carriage’. In this state, the
patient receives PD and may also receive
routine checks for the development of S. aureus
carriage. The risk of developing carriage and
hence the probability of moving to ‘On PD with
SA carriage’ may be affected by the use of some
form of prophylactic preventive treatment
either at the time of catheter insertion (the first
initial state of the model) or while on dialysis.
Patients in this state could potentially also
develop an infection, transfer to HD or die.
3. ‘On PD with SA carriage’. Patients in this state
are still on PD but are carriers of S. aureus. 
If S. aureus carriage were eradicated, the
patient would move back to the state ‘On PD
without SA carriage’. The patient could suffer
some form of infection although the risk of this
happening may be affected by any of the
methods of treating S. aureus carriage
(antibiotic sprays, ointment or powders).
Patients in this state could potentially also
transfer to HD or die.
4. ‘Infection’. While on PD, a patient may suffer an
exit-site infection, isolated tunnel infection or
peritonitis. The infections may occur either
separately or sequentially: exit site infection
leading to tunnel infection leading to
peritonitis. While in this state, patients face the
risk of losing their PD tube and moving into
temporary or permanent HD. Factors that
could make a person move from PD are
clearance failure, technique failure or recurrent
peritonitis. The types of infection and there
effects are:
(a) Exit-site infection, which is treated with
using a local treatment, systemic treatment
or catheter change. 
(b) Isolated tunnel infections, which are
treated using systemic treatments and/or
catheter removal. 
(c) Peritonitis infection, which is mainly due to
contamination and is treated with 2 weeks
of antibiotics administered peritoneally,
intravenously or orally. 
S. aureus infection can be cured without the
patient moving from PD (i.e. move to ‘On PD
without SA carriage’). If S. aureus infection is
not resolved, the catheter can be removed and
the treatment modality switched to ‘Temporary
HD’. Non-resolution of S. aureus infection can
be attributed to failure of antibiotics to clear
the infection (relapsing peritonitis) or it may
arise from an entirely new infection. Relapsing
peritonitis can be defined as the recurrence of
peritonitis caused by the same organism as the
immediately preceding episode of peritonitis
within 4 weeks of completion of antibiotic
treatment. The model would allow a patient to
have a maximum of between two and four
infections (i.e. to stay in the state of infection
for between two and four cycles) before the PD
catheter is removed, in which case the patient
would move to the state of ‘Temporary HD’. 
5. ‘Temporary HD’. As briefly described above,
there are several factors that could make a
person move from PD, such as clearance
failure, technique failure or recurrent
peritonitis. Once these factors are resolved
some patients may elect to move back to PD. If
they are not resolved, a patient may have to
stay in HD until they die (and hence move to
the state of ‘Permanent HD’). 
6. ‘Permanent HD’. Once a patient enters this state,
they do not leave it until they die.
7. ‘Dead’ (included as all-cause mortality). This
state can be entered from all preceding states. 
While the model allows for variation in the
parameters of the prevention and treatment of
peritonitis across each intervention (either
prophylactic prevention of S. aureus carriage or
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FIGURE 11 Draft model structure for the estimation of the relative cost-effectiveness of alternative methods to prevent and treat
S. aureus (SA) carriagetreatment of S. aureus carriage), it is necessary to
assume that many parameters will be the same
across the different branches. The following
section identifies the data required to populate the
model. To illustrate this description, the data
available for the comparison of the prophylactic
use of antibiotics at the time of catheter insertion
compared with no treatment have been used. 
Estimation of model parameters
A detailed description of the methods that might
be used to derive parameters for this model are
described in Appendix 7. In brief, this description
covers the derivation of transition probabilities,
costs and health state utilities. 
Assessment of cost-effectiveness
The results of the base-case analysis would be
based on the costs and outcomes faced by male
and female patients who initially started on PD. 
If the National Institute for Health and Clinical
Excellence (NICE) HTA guidelines were followed,
discount rates of 3.5% per annum would be
applied to both costs and health benefits.61 The
central outcomes of the analysis and the systematic
review would first be presented in terms of a
balance sheet. In the balance sheet the incremental
differences between the alternative interventions
would be presented in their natural units, such as
the number of patients with exit-site and/or tunnel
infections caused by S. aureus and number of
patients with peritonitis. The purpose of the
balance sheet is to illustrate the trade-offs that
would exist when choosing amongst interventions. 
Within the economic model, the different
outcomes would be combined into a single
measure of relative efficiency measured in terms of
the incremental cost per QALY. Data on the
incremental cost per QALY would be presented in
two ways. First, mean costs and QALYs for the
alternative interventions could be presented and
incremental cost per QALYs calculated where
appropriate. The second way in which the cost-
effectiveness of the alternative interventions might
be presented would be by cost-effectiveness
acceptability curves (CEACs). CEACs can be used
to illustrate the uncertainty caused by the
combined statistical variability in the model’s
parameter estimates. These curves illustrate the
likelihood that a strategy is cost-effective at various
threshold values for society’s willingness to pay for
an additional QALY. It should be noted that in
order to be able to perform the probabilistic
sensitivity analysis underpinning the estimation of
CEACs, all the parameters required for the model
should be described by an appropriate statistical
distribution that reflects the statistical imprecision
surrounding the point estimates (which has not
been attempted within this chapter). 
Additional analyses
The results of any economic evaluation will be
surrounded by uncertainty. In part, this will be
reflected by the probabilistic analysis that is
proposed above. However, other sensitivity
analyses would be required to address the
uncertainty around the available data or about the
way in which it would be used in the model. In
addition to the sensitivity analyses described
above, another potential sensitivity analysis might
focus on establishing at what point preventing or
treating carriage ceases to be cost-effective.
Examples of other potential sensitivity analyses are
described below. 
Risks of S. aureus carriage, risks of progression
to infection and other transition probabilities
Data on the prevalence of S. aureus carriage are
not available, yet it is likely that the cost-
effectiveness will be dependent on the proportion
of people starting PD who are carriers of S. aureus
and the risks of developing carriage and the
consequences of carriage in terms of the
development of infections and transitions to other
modalities of dialysis. 
Costs
The costs of antibiotics identified varied greatly.
The most expensive and least expensive costs
could be used in the sensitivity analysis. These
costs could be varied by increasing/reducing them
to establish at what cost prevention or treatment of
S. aureus carriage and infection ceased to be cost-
effective. Similarly, the costs of dialysis would also
be varied. This is because costs that would be used
in the base-case analysis although coming from a
very detailed costing exercise are derived from a
small number of centres and so might not be
generalisable to the rest of the NHS. The impact
of using other relevant costs such as those reported
in the NHS reference costs would be explored.
Utilities
The utility data used in the model were based on
non-randomised data. These data were based on
patient responses to the EQ-5D questionnaire
weighted using UK population tariffs. Further
analyses could be performed using the utility data
from other sources.
Results
Although no formal attempt to conduct the
proposed modelling exercise has been made, an
Health Technology Assessment 2007; Vol. 11: No. 23
25
© Queen’s Printer and Controller of HMSO 2007. All rights reserved.illustration of the limitations of the evidence base
is provided by presenting a balance sheet for the
comparison of the use of antibiotic versus no
antibiotic at catheter insertion (Table 11). As 
can be seen, the data available are very limited
and due to the paucity of data no further analyses
were carried out.
Summary
In this chapter, a hypothetical model for the
comparison of alternative methods to prevent or
treat S. aureus carriage has been presented. The
purpose of this exercise was to consider what
information would be required for an economic
evaluation and where the main information gaps
are. There is insufficient information on the
effectiveness and relative effectiveness of the
interventions that might be considered. Better
data are available for costs and utilities but further
data collection would be helpful. In particular,
evidence on the utility value for those
experiencing any of the infections would be useful. 
As the model is hypothetical, the structure
outlined in this chapter may need to be adapted
to reflect either new knowledge of the care
pathways, restrictions imposed by the data
available or the nature of the comparisons
considered. 
Economic evaluation
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TABLE 11 Balance sheet of antibiotic versus no antibiotic at catheter insertion and during dialysis
Favours antibiotic Favours no  Trials contributing 
intervention data
Trends towards fewer exit-site and/or tunnel infections (OR 0.15,  Lower costs 4
95% CI 0.06 to 0.3)
No statistically significant difference in 
number of patients with peritonitis (RR 0.73, 95% CI 0.31 to 1.72) 8
No information on:
Numbers of S. aureus carriage
Number of S. aureus cured
Number with relapse
Modality change rates
OR, odds ratio; RR, relative risk.Volume of evidence
There is a good number of trials but, as discussed
in Chapter 3, the quality of design, or at least of
reporting, is not good by today’s standards. The
first priority is to determine whether treatments
are effective, and this requires placebo controls.
Many of the trials were of one antibiotic or
antiseptic against another. Table 12 shows those in
which there was a placebo arm. The number falls
to 13. Some of these were very small, for example
those by Bennett-Jones and colleagues35 with 26
patients, Blowey and colleagues54 with 15 and
Sesso and colleagues58 with 31 amongst three
arms.
A number of the trials show a reduction in exit-site
infections but not in the incidence of peritonitis.
This may just be a power problem (exit-site
infections being much commoner than peritonitis,
plus the relatively small numbers involved), but
raises the question of the relationship between
carriage, infection and peritonitis. It is likely that
infection is introduced mainly at exchange via
contamination of the tip of the catheter, rather
than tracking along the tunnel. Better technique
might reduce the risk.
In an observational study, the Scottish Renal
Registry Group62 noted that peritonitis was 15%
(95% CI 4 to 26%) less common in units using
nasal mupirocin than those not, although this did
not apply to S. aureus peritonitis (one episode
every 106 months in user units versus one every
96 months in non-users; p = 0.52).
Other reviews
Our findings are similar to those of the Cochrane
Review by Strippoli and colleagues,63 who also
concluded that nasal mupirocin reduces exit-site
and tunnel infections, but not peritonitis. 
Guideline 3I of the European Guidelines30 states
that, “Use of mupirocin or gentamicin cream at
the exit site is recommended to reduce exit site
infections”, but cites no evidence that this reduces
peritonitis. Like the other guidelines, they have to
extrapolate from reduction in exit-site infections
to reduction in peritonitis.
One issue of concern has been the emergence of
resistance to mupirocin, especially in MRSA.
Mupirocin became available in 198564 and some
laboratories have reported increasing numbers of
mupirocin-resistant S. aureus, especially MRSA.64
Particularly high resistance rates have been
reported from New Zealand, but that may be
related to its availability over the counter without
prescription.65 In some European studies, high-
level mupirocin resistance was seen in only 2–3%
of S. aureus isolates,66,67 but there was variation
amongst countries, from 0% in most up to 6% in
Belgium and 5% in the UK. Much higher rates
have been reported in units with high mupirocin
use. In one neonatal intensive care unit, which
applied mupirocin routinely to insertion sites of
central venous catheters, resistance rates rose over
5 years to 42% of coagulase-negative staphylococci
(no results for S. aureus were reported), falling
again once the routine use was stopped.68
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Chapter 5
Discussion
TABLE 12 Summary list of trials of active agents against placebo
I.v. antibiotics Oral antibiotics Topical antibiotics Antiseptics
Prophylaxis
At first insertion Bennett-Jones, 198835 Waite, 199746
Lye, 199236
Gadallah, 200045
During later dialysis Zimmerman, 199139 Wong, 200338 Wong, 200249
Sharma, 197137 Luzar, 19903
Wilson, 199748
Eradication Blowey, 199454 Sesso, 199458 Mupirocin Study 
Sesso, 199458 Group, 199655Research needs
As the Cochrane Review said:63
“Given the large number of patients on PD and the
importance of peritonitis, the lack of adequately
powered RCTs to inform decision-making about
strategies to prevent peritonitis is striking.”
This is echoed in the UK guidelines:69
“We recommend that a large double-blind placebo
controlled study is now needed to confirm whether
mupirocin remains useful in clearing carriage in
patients or staff when low-level mupirocin resistance is
present.”
One of their concerns was that eradication of
carriage was lower in resistant strains, whether
they had high or low level resistance.
The key questions include:
1. What is the natural history and biology of
carriage? What are the links between carriage
and exit-site infection, and between exit-site
infection and peritonitis? How long does
carriage last for without treatment? How often
is it temporary rather than permanent? The
natural history of MRSA carriage suggests that
up to half of those colonised will clear
spontaneously within 1 year.70
2. How do we define carriage? Some centres take
swabs from multiple sites. But there is evidence
that eradication from the nose reduces carriage
elsewhere. Other sites include throat, groin,
gut, any wounds and the catheter. Site of
carriage seems to be important.
3. Treatment of carriage. Is MSSA relatively
harmless? MRSA carriage seems to be a much
stronger predictor of infection than MSSA
(about 50% by 18 months versus 2% with
MSSA).71 Should the focus be on those with
MRSA? Is decolonisation of proven
effectiveness, or is recolonisation rapid? Typing
of strains could separate relapse from
reinfection. Most decolonisation efforts are
directed to the nose, which is the most
common site of carriage, and to the catheter
insertion site, but topical application of
antibiotic or antiseptic to these sites will not
affect carriage elsewhere, unless carriage
elsewhere requires repeated spread of the
organism from its more favoured sites.
Individual strain type may also be important.
4. What other options for reducing peritonitis
might be tried? Would more training help?
5. What factors predict carriage – home contacts,
smoking, recent antibiotic treatment, recent
hospital admissions? The underlying disease,
such as diabetes, may affect susceptibility to
infection.
Eradication topics include:
● intermittent versus chronic
● antiseptics versus antibiotics
● the choice of drug
● is vaccination worth revisiting?
The design of any intervention trial should
consider confounding factors such as type of
catheter, training and automated PD versus
ambulatory PD.
The choice of antibiotic(s) to be tested in trials
should take into account susceptibility of
individual strains, and these may vary amongst
different dialysis centres. MRSA rates also vary,
and its presence is likely to compromise the
benefits of any -lactam antibiotic. MRSA strains
also vary in their susceptibility to other key
antibiotics such as gentamicin, rifampicin, fucidin,
neomycin and mupirocin, though probably not to
antiseptics. Long-term studies would be needed to
monitor the emergence of resistance – this is high
risk for agents such as mupirocin and rifampicin.
Some agents such as mupirocin, rifampicin and
fucidin are active mainly against Gram-positive
infections.
The widespread use of mupirocin, and the
concerns about resistance, make it a high priority
for research.
The key outcomes of research into prevention
would be:
● Episodes of peritonitis – average number per
patient per annum in population on PD in each
unit.
● Patient-based data – number of patients having
one or more episodes per annum, or over a
longer period; time from first insertion of
catheter to first episode of peritonitis. Even if
the number of infections was the same, delaying
infection would be a useful outcome.
● Numbers of temporary transfers to HD.
● Duration of successful treatment on PD.
Repeated episodes of peritonitis will shorten the
life of the peritoneal membrane as a dialysis
membrane.
Discussion
28T
he importance of peritonitis in PD is not in
doubt, and it remains the main cause of
transfer to HD. The evidence on prevention is
disappointing: exit-site infections are reduced but
not peritonitis, although this may be because the
studies were too small or too short, or because the
incidence of peritonitis was low. There is also some
concern about the development of resistance to
mupirocin amongst MRSA strains. More research
is required.
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Chapter 6
ConclusionsW
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36T
he following search strategies were used to
identify reports of RCTs and systematic
reviews evaluating the effectiveness of preventing
and treating Staphylococcus aureus carriage on
peritoneal catheter-related infections.
MEDLINE (1996–November Week 3 2005),
EMBASE (1980–Week 1 2006) (MEDLINE Extra
6 January 2006)
Ovid Multifile Search. URL:
http://gateway.ovid.com/athens
1 exp peritoneal dialysis/ 
2 continuous ambulatory peritoneal dialysis/ use
emez 
3 peritoneal dialysis.tw. 
4 (capd or ccpd or apd).tw. 
5 or/1-4 
6 staphylococcal infections/pc 
7 peritonitis/pc 
8 bacterial peritonitis/pc use emez 
9 catheterization/ae use mesz 
10 catheterization/ use emez 
11 catheters, indwelling/ae use mesz 
12 indwelling catheter/ use emez
13 surgical wound infection/ use mesz 
14 surgical infection/ use emez 
15 catheter exit$.tw. 
16 exit site$.tw. 
17 (catheter adj3 infect$).tw. 
18 (catheter adj3 infect$).tw.
19 (tunnel adj3 infect$).tw. 
20 or/13-19 
21 (prevent$ or prophyla$ or reduc$ or limit$).tw. 
22 20 and 21 
23 or/6-12,22 
24 5 and 23
25 staphylococcus aureus/ 
26 bacterium carrier/ use emez 
27 bacterial colonization/ use emez 
28 methicillin resistance/ use mesz 
29 vancomycin resistance/ use mesz 
30 methicillin resistant staphylococcus aureus/ use
emez 
31 aureus.tw. 
32 (msra or mssa or visa or vrsa).tw. 
33 (carriage or carrier$ or host$).tw. 
34 (colony or coloni?ation).tw. 
35 33 or 34
36 or/25,28-32 
37 35 and 36
38 or/26-27,37 
39 5 and 38
40 antibiotic prophylaxis/
41 exp anti-infective agents/
42 or/40-41
43 5 and (25 or 31) and 42
44 24 or 39 or 43 
45 animal/ not human/ use mesz
46 (animal/ or nonhuman/) not human/ use emez 
47 44 not (45 or 46) 
48 clinical trial.pt. use mesz 
49 exp controlled clinical trials/ use mesz 
50 randomised controlled trial/ use emez 
51 clinical trial/ use emez
52 random allocation/ use mesz 
53 randomization/ use emez 
54 placebo effect/ use mesz
55 placebo/ use emez 
56 random$.tw. 
57 placebo$.tw. 
58 or/48-57 
59 meta analysis.tw. 
60 meta analysis.pt. use mesz 
61 meta analysis/ use emez 
62 review.ab. 
63 review.pt. use mesz 
64 systematic review/ use emez
65 or/60-65
66 47 and (59 or 66) 
67 67 and eng.la. 
68 remove duplicates from 68 
CINAHL (1982–December Week 2 2005) 
Ovid Multifile Search. URL:
http://gateway.ovid.com/athens
1 exp peritoneal dialysis/ 
2 peritoneal dialysis.tw. 
3 (capd or ccpd or apd).tw. 
4 or/1-3 
5 staphylococcal infections/pc 
6 peritonitis/pc 
7 catheterization/ae 
8 catheters, dialysis/ae 
9 catheter-related infections/ 
10 catheter exit$.tw. 
11 exit site$.tw. 
12 (catheter adj3 infect$).tw. 
13 (tunnel adj3 infect$).tw. 
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Search strategies14 or/9-13 
15 prevent$ or prophyla$ or reduc$ or 
limit$).tw. 
16 14 and 15 
17 or/5-8,16 
18 4 and 17
19 Staphylococcus Aureus/ 
20 methicillin resistance/ 
21 vancomycin resistance/
22 aureus.tw. 
23 (msra or mssa or visa or vrsa).tw.
24 bacterial colonization/ 
25 carrier state/ 
26 (carriage or carrier$ or host$).tw. 
27 (colony or coloni?ation).tw. 
28 or/25-27 
29 or/19-23 
30 28 and 29 
31 24 or 30 
32 4 and 31
33 antibiotic prophylaxis/ 
34 exp antiinfective agents/ 
35 or/33-34 
36 4 and (19 or 22) and 35 
37 18 or 32 or 36 
38 37 and eng.lg. 
Science Citation Index (1985–7 January 2006)
SCI Proceedings (1990–6 January 2006)
Web of Knowledge URL: http://wok.mimas.ac.uk/ 
#1 TS=(capd OR ccpd OR apd)
#2 TS=(peritoneal SAME dialysis)
#3 #1 OR #2
#4 TS=(coloni* SAME (aureus OR msra OR
mssa OR visa OR vrsa))
#5 TS=(colony SAME (aureus OR msra OR
mssa OR visa OR vrsa))
#6 TS=(host* SAME (aureus OR msra OR mssa
OR visa OR vrsa))
#7 TS=(carrier* SAME (aureus OR msra OR
mssa OR visa OR vrsa))
#8 TS=(carriage SAME (aureus OR msra OR
mssa OR visa OR vrsa))
#9 TS=((methicillin OR vancomycin) SAME
resist*)
#10 #4 OR #5 OR #6 OR #7 OR #8 OR #9
#11 #3 AND #10
#12 TS=((prevent* OR prophyla* OR reduc* OR
limit*) SAME staphylococcal)
#13 TS=((prevent* OR prophyla* OR reduc* OR
limit*) SAME aureus)
#14 TS=((prevent* OR prophyla* OR reduc* OR
limit*) SAME peritonitis)
#15 TS=(catheter* SAME infect*)
#16 TS=(tunnel SAME infect*)
#17 TS=(exit* SAME (catheter* OR site*))
#18 #12 OR #13 OR #14 OR #15 OR #16 OR
#17
#19 #3 AND #18
#20 #11 OR #19
#21 TS=randomized
#22 TS=randomised
#23 TS=random
#24 TS=randomly
#25 TS=random* assign*
#26 TS=random* alloc*
#27 TS=(control* SAME trial*)
#28 TS=meta analysis
#29 TS=systematic review*
#30 #20 AND (#21 OR #22 OR #23 OR #24
OR #25 OR #26 OR #27 OR #28 OR #29)
DocType=All document types; Language=All
languages
BIOSIS (1985–3 January 2006)
Edina URL: http://edina.ac.uk/biosis/
((((((al: (meta analysis) or al: (systemtic review*))
and ()) or ((al: (random or randomly) or al:
(control* n3 trial*)) and ())) or ((al: (randomized
or randomised) or al: (random* alloc*) or al:
(random* assign*)) and ()))) and (((((((((al: (exit*
n3 catheter*) or al: (exit* n3 site*)) and ()) or ((al:
(catheter* n3 infect*) or al: (tunnel n3 infect*))
and ())) or ((al: (prevent* or prophyla* or reduc*
or limit*) and al: (staphylococcal or aureus or
peritonitis)) and ()))) and ((((al: (peritoneal n3
dialysis)) and ()) or ((al: (capd) or al: (ccpd) or al:
(apd)) and ()))))) or ((((((al: (methicillin n3 resist*)
or al: (vancomycin n3 resist*)) and ()) or (al:
(aureus or mrsa or mssa or visa or vrsa) and al:
(carriage or carrier* or host* or colony or
coloni*)))) and ((((al: (peritoneal n3 dialysis)) and
()) or ((al: (capd) or al: (ccpd) or al: (apd)) and
())))))))) 
Clinical Trials (December 2005)
URL: http://clinicaltrials.gov/ct/gui/c/r
Current Controlled Trials (December 2005) 
URL: http://www.controlled-trials.com/
Aureus AND (peritoneal OR CAPD)
Cochrane Library Issue 4, 2005
URL: http://www3.interscience.wiley.com/cgi-bin/
mrwhome/106568753/HOME
National Research Register (Issue 4, 2005)
URL: http://www.update-software.com/National/
#1 MeSH descriptor Peritoneal Dialysis explode
all trees in MeSH products 
#2 peritoneal dialysis in All Fields in all products 
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38#3 capd in All Fields or ccpd in All Fields or apd
in All Fields in all products 
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Staphylococcal Infections
explode all trees with qualifier: PC in MeSH
products
#6 MeSH descriptor Peritonitis explode all trees
with qualifier: PC in MeSH products 
#7 MeSH descriptor Catheterization explode all
trees with qualifier: AE in MeSH products 
#8 MeSH descriptor Catheters, Indwelling
explode all trees with qualifier: AE in MeSH
products 
#9 MeSH descriptor Surgical Wound Infection
explode all trees in MeSH products
#10 exit site* in All Fields or catheter NEAR/3
infect* in All Fields or tunnel NEAR/3 infect*
in All Fields or catheter exit* in All Fields in
all products 
#11 (#9 OR #10) 
#12 prevent* in All Fields or prophyla* in All
Fields or reduc* in All Fields or limit* in All
Fields in all products
#13 (#11 AND #12) 
#14 (#5 OR #6 OR #7 OR #8 OR #13) 
#15 (#4 AND #14) 
#16 MeSH descriptor Staphylococcus aureus
explode all trees in MeSH products
#17 aureus in All Fields in all products 
#18 mrsa in All Fields or mssa in All Fields or
visa in All Fields or vrsa in All Fields in all
products 
#19 MeSH descriptor Methicillin Resistance
explode all trees in MeSH products
#20 MeSH descriptor Vancomycin Resistance
explode all trees in MeSH products 
#21 carriage in All Fields or carrier* in All Fields
or host* in All Fields in all products 
#22 colony in All Fields or colonization in All
Fields or colonisation in All Fields in all
products 
#23 (#16 OR #17 OR #18 OR #19 OR #20) 
#24 (#21 OR #22)
#25 (#23 AND #24) 
#26 (#4 AND #25) 
#27 MeSH descriptor Antibiotic Prophylaxis
explode all trees in MeSH products
#28 MeSH descriptor Anti-Infective Agents
explode all trees in MeSH products 
#29 (#27 OR #28) 
#30 (#16 OR #17) 
#31 (#4 AND #29 AND #30) 
#32 (#15 OR #26 OR #31)
DARE and HTA Databases (December 2005)
NHS Centre for Reviews and Dissemination 
URL: http://nhscrd.york.ac.uk/welcome.htm
Peritoneal-dialysis (exploded) or capd
and
aureus
Conference proceedings abstracts screened
1st Asian Chapter Meeting ISPD, Hong Kong,
December 2002, Perit Dial Int 2003;23(Suppl 2).
2nd Asian Chapter Meeting, Hyderabad, India,
January 2005, Perit Dial Int 2005;25(Suppl 2).
1st Joint ISPD/EUROPD Congress, Amsterdam,
August 2004, Perit Dial Int 2004;24(Suppl 2).
Journals full text screened
Peritoneal Dialysis International (1981–2005)
Advances in Peritoneal Dialysis (1985–2004)
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Study ID:  Refman ID: 
Type of study
Q1. Is the study a randomised controlled trial or a quasi-randomised  Yes Unclear No
controlled trial? 
Go to  Exclude
Next question
Participants in the study
Q2. Were the participants in the study adult or paediatric patients  Yes Unclear No
undergoing peritoneal dialysis or about to undergo a peritoneal 
catheter placement procedure? 
Go to  Exclude
Next question
Interventions in the study
Q3. Did one group receive antimicrobial treatment, antiseptic  Yes Unclear No
medication or other intervention to prevent or treat S. aureus
carriage? 
Go to  Exclude
Next question
Q4. Did another group receive a different intervention or no treatment  Yes Unclear No
to prevent or treat S. aureus carriage? 
Go to  Exclude
Next question
Outcomes in the study
Q5. Did the study report any of the pre-specified outcomes (refer to  Yes Unclear No
data abstraction and quality assessment form) 
Include, subject  Exclude
to clarification of 
‘unclear’ points
Final decision:
Include trial Background information Economic data Systematic review
Unclear Exclude
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Study eligibility formEffectiveness of preventing and treating Staphylococcus aureus carriage
on peritoneal catheter-related infections
Reviewer ID: 
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Appendix 3
Data abstraction and quality assessment form
Study Details
Study ID: Abstract Full text Unpublished
Authors:
Title:
Publication year or date of interim data collection: 
Quality assessment
Allocation concealment: Adequate Inadequate Unclear
Blinding:
Blinding of investigators: Yes No Unclear
Blinding of participants: Yes No Unclear
Blinding of outcome assessor: Yes No Unclear
Blinding of data analysis: Yes No Unclear
Intention to treat analysis:
Stated & confirmed ITT Not stated but confirmed ITT
Not stated but confirmed not ITT Stated but not confirmed not ITT
Not stated
Participants lost to follow-up Yes No Unclear
Percent of participants excluded or lost to follow-up:
Study Design
RCT Quasi RCT
Prevention trial Treatment trial
Randomisation details Appendix 3
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Participants
Number of participants randomised or included in trial: 
Proportion of numbers in clinic included in trial: 
Criteria for inclusion:  Criteria for exclusion: 
Setting and Timing
Setting of study:
Recruitment period:
Follow-up period:
Screening and treatment of nasal S. aureus
Screening: 
Treatment 
Interventions
Treatment/Prevention No of patients
Intervention 1
Intervention 2
Intervention 3Health Technology Assessment 2007; Vol. 11: No. 23
45
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Patient Characteristics
Intervention 1 Intervention 2 Intervention 3
Age (years)
Sex (M/F)
Adults (No)
Paediatrics (No)
Diabetic Nephropathy (No)
Hypertension and 
Renovascular Disease (No)
Glomerulonephritis (No)
Adult Polycystic Kidney 
Disease (No)
Reflux Nephropathy (No)
E coli 0157 (No)
Other aetiology 
(No & specify)
Time on PD before treatment 
Indications of infirmity 
(specify)
Hygiene measures taken 
(specify)Appendix 3
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Outcomes
Intervention 1 Intervention 2 Intervention 3
No of patients with S. aureus
carriage
Time to S. aureus carriage
No of patients with peritonitis
Peritonitis rate (no of episodes 
over total pt months on PD)
Time to first peritonitis 
episode
Peritonitis relapse (No & 
specify time to)
No of patients requiring 
catheter removal
No of patients switching to 
haemodialysis
No of patients requiring 
catheter replacement
No of patients with exit-site 
and tunnel infections
Exit-site and tunnel infection 
rate
Side effects of antibiotics
Death due to peritonitis
Hospitalisation rates
Quality of life
Development of antibiotic 
resistanceBennett-Jones, 1988
Bennett-Jones DN, Martin J, Barrett A, Duffy TJ, Naish
PF, Aber GM. Prophylactic gentamicin in the prevention
of early exit-site infections and peritonitis in CAPD. Adv
Perit Dial 1988;4:147–50.
Bernardini, 1996
Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R.
A randomized trial of Staphylococcus aureus prophylaxis
in peritoneal dialysis patients: mupirocin calcium
ointment 2% applied to the exit site versus cyclic oral
rifampin. Am J Kidney Dis 1996;27:695–700.
Bernardini, 2005
Primary reference
Bernardini J, Bender F, Florio T, Sloand J,
Palmmontalbano L, Fried L, et al. Randomized, double-
blind trial of antibiotic exit site cream for prevention of
exit site infection in peritoneal dialysis patients. J Am
Soc Nephrol 2005;16:539–45.
Secondary reference
Bernardini J, Fried L, Bender F, Sloand J,
Palmmontalbano L, Florio T, et al. A randomized
double-blind trial of PD infection comparing mupiocin
to gentamicin sulfate cream. Perit Dial Int 2004;
24(Suppl 2):S53.
Blowey, 1994
Blowey DL, Warady BA, McFarland KS. The treatment
of Staphylococcus aureus nasal carriage in pediatric
peritoneal dialysis patients. Adv Perit Dial 1994;10:297–9.
Cavdar, 2004
Cavdar C, Zeybel M, Atay T, Sifil A, Sanlidag C, Gulay Z,
et al. The effects of once- or thrice-weekly mupirocin
application on mupirocin resistance in patients on
continuous ambulatory peritoneal dialysis – first
6 months’ experience. Adv Perit Dial 2004;20:62–6.
Fuchs, 1990
Fuchs J, Gallagher ME, Jackson-Bey D, Krawtz D,
Schreiber MJJ. A prospective randomized study of
peritoneal catheter exit-site care. Dial Transplant 1990;
19:81–4.
Gadallah, 2000
Primary reference
Gadallah MF, Ramdeen G, Torres C, Mignone J, Patel D,
Mitchell L, et al. Preoperative vancomycin prophylaxis
for newly placed peritoneal dialysis catheters prevents
postoperative peritonitis. Adv Perit Dial 2000;16:199–203.
Secondary reference
Gadallah MF, Ramdeen G, Mignone J, Patel D, 
Mitchell L, Tatro S. Role of preoperative antibiotic
prophylaxis in preventing postoperative peritonitis in
newly placed peritoneal dialysis catheters. Am J Kidney
Dis 2000;36:1014–19.
Luzar, 1990
Luzar MA, Brown CB, Balf D, Hill L, Issad B, Monnier B,
et al. Exit-site care and exit-site infection in continuous
ambulatory peritoneal dialysis (CAPD): results of a
randomized multicenter trial. Perit Dial Int 1990;10:25–9.
Lye, 1992
Lye WC, Lee EJ, Tan CC. Prophylactic antibiotics in the
insertion of Tenckhoff catheters. Scand J Urol Nephrol
1992;26:177–80.
Mupirocin Study Group, 1996
Primary reference
Mupirocin Study Group. Nasal mupirocin prevents
Staphylococcus aureus exit-site infection during peritoneal
dialysis. Mupirocin Study Group. J Am Soc Nephrol 1996;
7:2403–8.
Secondary reference
Davey P. Randomised clinical trial and cost analysis of
mupirocin for prevention of exit site infections (ESI) in
continuous ambulatory peritoneal dialysis (CAPD).
Abstracts of the Interscience Conference on Antimicrobial
Agents and Chemotherapy 1996;36:296.
Perez-Fontan, 1992
Perez-Fontan M, Rosales M, Rodriguez-Carmona A,
Moncalian J, Fernandez-Rivera C, Cao M, et al.
Treatment of Staphylococcus aureus nasal carriers in
CAPD with mupirocin. Adv Perit Dial 1992;8:242–5.
Poole-Warren, 1991
Poole-Warren LA, Hallett MD, Hone PW, Burden SH,
Farrell PC. Vaccination for prevention of CAPD
associated staphylococcal infection: results of a
prospective multicentre clinical trial. Clin Nephrol 1991;
35:198–206.
Sesso, 1988
Sesso R, Barbosa D, Sato I, Draibe S, Castelo A, Ajzen H.
A randomized controlled trial to assess the effectiveness
of daily baths with 4% chlorhexidine gluconate vs
neutral soap in CAPD patients. Perit Dial Int 1988;8:288.
Sesso, 1994
Sesso R, Parisio K, Dalboni A, Rabelo T, Barbosa D,
Cendoroglo M, et al. Effect of sodium fusidate and
ofloxacin on Staphylococcus aureus colonization and
infection in patients on continuous ambulatory
peritoneal dialysis. Clin Nephrol 1994;41:370–6.
Sharma, 1971
Sharma BK, Rodriguez H, Gandhi VC, Smith EC, 
Pillay VK, Dunea G. Trial of oral neomycin during
peritoneal dialysis. Am J Med Sci 1971;262:175–8.
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List of included studiesTurner, 1992
Turner K, Edgar D, Hair M, Uttley L, Sternland R,
Hunt L, et al. Does catheter immobilization reduce exit-
site infections in CAPD patients? Adv Perit Dial 1992;
8:265–8.
Waite, 1997
Waite NM, Webster N, Laurel M, Johnson M, Fong IW.
The efficacy of exit site povidone–iodine ointment in
the prevention of early peritoneal dialysis-related
infections. Am J Kidney Dis 1997;29:763–8.
Warady, 2003
Warady BA, Ellis EN, Fivush BA, Lum GM, 
Alexander SR, Brewer ED, et al. “Flush before fill” in
children receiving automated peritoneal dialysis. Perit
Dial Int 2003;23:493–8.
Wilson, 1997
Wilson AP, Lewis C, O’Sullivan H, Shetty N, Neild GH,
Mansell M. The use of povidone iodine in exit site care
for patients undergoing continuous peritoneal dialysis
(CAPD). J Hosp Infect 1997;35:287–93.
Wong, 2002
Wong FSY, Chan W-K, Chow N-Y, Tsui Y-T, Yung JCU,
Cheng Y-L. Comparison of exit-site infection with the
use of pure liquid soap and chlorhexidine soap in daily
exit-site care. Hong Kong J Nephrol 2002;4:54–9.
Wong, 2003
Wong SSH, Chu K-H, Cheuk A, Tsang WK, Fung SKS,
Chan HWH, et al. Prophylaxis against Gram-positive
organisms causing exit-site infection and peritonitis in
continuous ambulatory peritoneal dialysis patients by
applying mupirocin ointment at the catheter exit site.
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Zimmerman, 1991
Zimmerman SW, Ahrens E, Johnson CA, Craig W,
Leggett J, O’Brien M, et al. Randomized controlled trial
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As mentioned before, the main source of
effectiveness data that would be used to populate
the model is the review of effectiveness (Chapter 3).
However, as described below, other sources such as
existing datasets and population cohort studies
may be required. The outcomes of the systematic
review of effectiveness were primarily presented in
terms of relative effect sizes (RRs) for the
comparison of prophylactic antibiotic with no
treatments. By identifying the relevant transition
probabilities for the ‘no treatment’ intervention
and combining with relevant relative effect sizes
for the prophylactic antibiotic intervention, the
transition probabilities for this intervention can be
derived.
Estimation of baselines comparator
transition probabilities 
One source of data on the relevant transition
probabilities for this is the control arms of studies
that compared an active treatment with no
treatment. Table 13 describes the parameters used
to determine transitions between the states of the
model. The data that might be used for these
parameters are described below.
Transition probabilities from ‘Catheter
insertion’
Following the initial insertion of the PD catheter a
person would receive PD, although they may have
a risk of being a carrier of S. aureus. Ideally, the
risk of S. aureus carriage would come from a large
population based survey of patients pre-dialysis.
Some data on the risk of S. aureus carriage at the
time of catheter insertion could be obtained from
systematic review of effectiveness36,46 (see Table 6).
These sources provide rates of S. aureus carriage of
between 18.0 and 30.8% and a crude mean of
27.0% (46 cases out of 167 trial participants). In
the model, it would be assumed that 27% of those
who do not die less those who experience an
infection (see below) would transfer into the state
of ‘On PD with SA carriage’. 
The risk of infections caused by S. aureus following
catheter insertion could also be provided by review
of effectiveness data. The systematic review of
effectiveness sought to identify the number of
patients with peritonitis, peritonitis rates,
peritonitis relapses, exit-site and tunnel infection
rates. Although the aim was to identify exit-site,
tunnel and peritonitis infections separately, most
of the studies reported exit-site/tunnel infections
together (Chapter 3). Table 6 provides details on
the number of patients without S. aureus carriage
who develop peritonitis and also the mean
number of episodes per patient year. The data
from the no treatment arms of these studies can
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Appendix 7
Proposed methods for parameterising the
economic model
TABLE 13 Baseline parameter values required for the model
State Parameter
‘Catheter insertion’ On PD without SA carriage
On PD with SA carriage
On PD with an infection
‘On PD without SA’ Remain on PD without SA 
carriage
On PD with SA carriage
On PD with an infection
Transfer to HD
Die
‘On PD with SA’ Go back to PD without SA 
carriage
Remain on PD with SA carriage
On PD with an infection
Transfer to HD
Die
‘Infection’a Infection cured, return to PD 
without SA carriage
Relapsing infection
Temporary HD
HD
Die
‘Temporary HD’ Infection cured, return to PD 
without SA carriage
HD
Die
‘Permanent HD’ Remain on HD
Die
a In the hypothetical model, ‘infection’ is defined as a
single state. In a full model, the different types of
infection might be defined as individual states that
would allow them to occur either singularly or in
sequence.be used to provide some information of the risks
of infection (and types of infection) per year.
However, very few data are available.39 A crude
estimate of the risk of peritonitis per patient per
month would be 1.3%. A similar estimate for the
risk of exit-site or tunnel infections would be 5.4%.
Such data come from a small study and hence are
imprecise and unreliable.39 Ideally, such data
would be replaced by data from a larger study.
Data are also required on the risk of infections for
those with S. aureus carriage. Data from the no
treatment arms for comparisons of alternative
methods to treat S. aureus carriage provided by the
systematic review are one source of data55 (Table 8).
However, such data are not comparable to the
risks of infections for those without S. aureus
carriage. For example, from the data available, the
risk of peritonitis per patient per month can be
calculated as 1.9% and the risk of exit-site and
tunnel infections as 3.6%. It might be expected
that the infections caused by S. aureus would be
greater in the group that were known carriers of
S. aureus. Ideally, the information on infection
rates amongst those who are and are not carriers
of S. aureus would come from a single study of
sufficient size to provide reasonably precise and
reliable data for a UK setting.
Survival rates or death rates for patients on PD
would also be needed. The Renal Registry has
published survival rates derived from data on 
3-year survival rates using Kaplan–Meier survival
analysis.1 To use such data would require that the
proportion of people dying from S. aureus
infection while on PD is only a small proportion of
the total risk of death on PD. 
Transition probabilities from ‘On PD
without SA carriage’
Patients who are S. aureus free can remain on PD
until they die either free of S. aureus carriage or
become carriers of S. aureus. These is insufficient
information on the risk that a patient might
develop S. aureus carriage from the review of
effectiveness, but one study reported how the risk
of S. aureus nasal carriage changes over time.51
This study is small and even though such data
could be used in the model, they are likely be 
both imprecise and unreliable. Ideally, such data
should come from the control arm of a large RCT
or from a large cohort study relevant to a UK
setting.
As indicated in Table 10, a patient on PD but free
of S. aureus also faces the probability of developing
an infection or dying. The data required to derive
the relevant transition probabilities could be
derived using similar methods to those outlined
for the transitions from ‘Catheter insertion’.
The remaining transition probability required
from the state ‘On PD without SA carriage’ is the
transition to HD. The review of effectiveness
sought to establish the number of patients
requiring catheter replacement/removal (and
hence requiring temporary HD, a clinically
possible transition but not one allowed for this
state in this hypothetical model) and the number
of patients permanently switching to HD (unclear
whether this included both permanent and
temporary transfers). Although some data were
reported on catheter removal for those with
S. aureus carriage (see Table 6), no data were
identified on the number of patients switching
modality. A search of the Renal Registry indicated
that the sequential annual risk of switching from
PD to HD permanently was 11% at the end of the
first year, 18% at the end of the second year and
23% at the end of the third year (based on data
for patients established on PD in 1998–9, the most
recent years for which data are available).1 From
such data, monthly transition probabilities might
be estimated. 
Transition probabilities from ‘On PD
with SA carriage’
Similar methods and data sources would be
required to estimate the transition probabilities
from this state as those described for transitions
from ‘Catheter insertion’ and ‘On PD without SA
carriage’. 
Transition probabilities from ‘Infection’
Ideally, the likelihood that an infection is cured
would be derived by consideration of the data on
the effectiveness of interventions to treat S. aureus
interventions. The most appropriate source of
such data would not be the review of effectiveness
reported in Chapter 3 but a new review of studies
looking at alternative treatments of infections (the
data from such a review are presented in
Appendix 8). From such a review, data would be
extracted on the likelihood of infections that do
not resolve and the risk of death or transferring
modality. Following consultation with the clinical
co-reviewers, it has been assumed in the model
that should a patient suffer three consecutive
months (cycles) of infection that they would
automatically transfer to the state of temporary HD. 
Transition probabilities from
‘Temporary HD’
Patients who enter this state will remain in it for
only one cycle; at the end of that cycle, they may
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carriage’, transfer to the state of ‘Permanent HD’
or die. The risk of death is not likely to be greatly
different to the rates used for earlier states.
However, there is no evidence available on the
likelihood of returning to PD or moving to
permanent HD. Data from the Renal Registry
suggest that patients rarely switch from HD to PD
(approximately 3% per annum), but these
numbers may not be applicable for the group of
patients who switch to HD only until their
symptoms resolve. Ideally, data from a well-
designed study would be useful but, as this is only
a transitory state, sensitivity analysis could be
conducted over a range of plausible values.
Transitions from ‘Permanent HD’
In the model, it is assumed that once patients are
transferred to HD they will stay in this state until
they die. The Renal Registry has published
survival rates using Kaplan–Meier survival analysis
and these data could be used to establish the
relevant transition probabilities. 
Estimation of relative effect sizes
Data on relative effect sizes for an active treatment
compared with no treatment (e.g. antibiotics
versus no antibiotics for the prevention of
carriage) can, when combined with the transition
probabilities for no treatment, be used to estimate
the transition probabilities for the an active
treatment, e.g. prophylactic antibiotics. The
various relative effect sizes estimated as part of the
review of effectiveness are presented in Figures 1–7.
Although such relative effect sizes could be used in
a model, they are limited as they are based on
sparse data, and a full evaluation comparing all
relevant interventions would rely on indirect
comparisons. Details of the data available for
comparison of antibiotics provided at the time of
catheter insertion compared with no treatment are
provided below.
S. aureus carriage cure rates
This relative effect size is needed to estimate the
probability of entering ‘PD without SA carriage’
and ‘PD with SA carriage’ states following
prophylactic use of antibiotics at the time of
catheter insertion. From the review of
effectiveness, no data were available on the ability
of prophylactic antibiotics at the time of catheter
insertion to prevent infection with S. aureus. Some
estimate could be obtained by considering the
effectiveness of antibiotics at curing those with
known S. aureus carriage. Table 8 reports the
results on the number of people treated for
S. aureus carriage during dialysis. The number of
patients cured (those who did not have S. aureus at
the end of the treatment) could therefore be
derived from these data. 
S. aureus infection rates
These relative effect sizes would be used to
estimate the likelihood of developing an infection.
Data are not available split by whether the
infections occurred in those who were S. aureus
carriers and those who were not. Although
consideration of data provided in Figures 1, 2, 5
and 6 might provide some information with which
plausible estimates could be derived. Nevertheless,
ideally such data would be more usefully derived
from the participant-level data from a large
controlled study. 
Exit site/tunnel and peritonitis cure
rates
Once an infection has occurred, the assumption
would be made that the probability of cure would
be independent of the intervention used to
prevent or treat S. aureus carriage. Thus, the
transition probabilities from the state of ‘Infection’
following the use of prophylactic antibiotics would
be the same as those following no treatment. What
would vary between the two interventions would
be the probability of an infection. 
Modality changes
Few studies provided any data on the number of
patients switching modality from PD or the
number of patients requiring catheter removal
(and at least a move to temporary HD). The
studies identified in Chapter 3 were not designed
to provide such data and provided, at best, only
proxy indicators. Such data as are available are
presented in Tables 6 and 8 but are both imprecise
and potentially unreliable due to the small size of
the studies. Furthermore, such data would ideally
be split by those who were S. aureus carriers and
those who were not carriers. Ideally, such data
would be more usefully derived from the
participant-level data from a large controlled study. 
Relative effect sizes for the risk of modality
changes from the states of ‘Infection’, ‘Temporary
HD’ and ‘Permanent HD’ would not be required
as these transition probabilities are assumed to be
independent of the method used to prevent or
treat S. aureus carriage. 
Death or survival rates
Exactly the same situation arises for relative effect
sizes associated with the risk of death as those
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from a large controlled study would be useful.
Such a study would need to have sufficiently long
enough follow-up to capture differences in survival
(and other relevant effects).
Cost data
The perspective of the assessment of costs would
be that of the NHS and Personal Social Services.
Resource use data would be identified from
published studies, healthcare service utilisation
data and advice from experts in this field. Cost
data used to illustrate this part of the hypothetical
model were mainly extracted from the literature
published in 1999 and were inflated to 2005 using
the Hospital and Community Health Services
(HCHS) pay and price inflation indices72 and the
currency used is pounds sterling (£). The main
cost components were the costs of the
interventions themselves and the costs of treating
an infection or the consequences of an infection
(e.g. a change in modality or the replacement of a
catheter). Details of the cost values used are
reported in Table 14 and the methods used to
derive these values are described below. 
Estimation of the cost of catheter
insertion
The cost of inserting a peritoneal catheter was
derived from Kirby and Vale.73 These costs were
calculated by identifying items of resource use
from studies and by consulting the renal
administrator at NHS Grampian. Local prices
were then attached to each item and drug costs
obtained from nationally available sources. The
cost of access was estimated at £1955 in 1999
(£2235 in 2004 prices). The same cost would be
used for patients who required a replacement 
of a PD catheter (following a period on 
temporary HD). 
Estimation of the cost of interventions
to prevent or treat S. aureus carriage
Data on patients who received antibiotics were
derived from a published study.59 The cost data
reported were based on the consideration of the
unit dose, route of administration, doses per day
and duration of therapy. The total cost of 1 year’s
treatment per identified carrier of S. aureus was
£157 (at 1994 prices) and this comprised costs of
£64 for screening and £93 for antibiotics. These
costs were based on one antibiotic (mupirocin).
The inflated annual cost per identified carrier of
S. aureus is £179 (£73 for screening and £106 for
antibiotic).
Estimation of the costs of treating
infections
Data on patients who received antibiotics were
derived from a published study59 and the costs of
treatment were comprised of unit dose, route of
administration, doses per day and duration. The
study indicated that the mean costs of treating
infections were highly skewed. The mean costs of
treating all infections (exit-site infections and
other infections) was £178 for the prophylaxis
group and £379 for the placebo group at 1994
prices. The difference between the means was not
statistically significant –£201 (–£493 to £90). The
cost data inflated to 2005 prices were £203 for the
prophylaxis group and £433 for the placebo
group.
Estimation of the costs of providing
dialysis
The cost data for these interventions included
consumables such as catheters and prophylactic
treatments, staff costs, capital costs of providing
HD, overheads and transport where necessary.
These data were based on data provided by the
EURODICE study (Wordsworth S, Health
Economist, Oxford: personal communication,
2005). This study was an observational study
investigating the costs, effects and cost-
effectiveness of PD and HD in 10 European
centres, two of which were in the UK. Costs in
each centre were detailed data on the use of
resources required for the different dialysis
modalities in use. These were collected between
1999 and 2001 during site visits, detailed
examination of records and the completion of
questionnaires by manager, healthcare
professionals and patients. In this review, data
from the two UK centres (Aberdeen and Dundee)
would be used as they are most likely to be
applicable to the UK. The five main categories
included in the estimation of costs were
consumables, staff, capital, overheads and patient
transport. The consumables were composed
mainly of disposable items such as dialysers, line
and recombinant human erythropoietin (EPO).
Staff costs were based on weekly work rosters from
the units which detailed the time devoted to the
provision of HD and PD. The capital costs for HD
were composed of building costs, dialysis machine,
repairs, water treatment and computers. Although
PD typically takes place outwith the hospital, some
hospital costs would normally be incurred. The
capital costs of PD were based on building costs,
weighing scales, bag warmers, drip stand and
blood pressure monitor. Staff costs were derived by
identifying the salary grades of those who spent
time with the patients (both medical and nursing)
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patients. Overhead costs included floor space
allocation that was composed of cleaning,
building, engineering, local government authority
taxation on buildings (rates), water, energy and
occupied bed days allocation that were composed
of medical records, linen and catering. The total
cost of HD for 1 month was £2458 and for PD
£1603 at 2005 prices.
Estimation of costs of change in
modality
One of the main effects of infections is the need to
remove and replace the catheter and the cost of
change in modality of treatment. The cost of loss
of catheter/catheter replacement is based on the
cost of a catheter, which is £2235 as reported
above. The cost of switch in modality is the cost of
HD, including creation of the access fistula. These
data were also derived from Kirby and Vale and
were estimated using the same methods as
described for the cost of catheter insertion.73 The
cost was £1959 (1999 prices), which was inflated to
£2240 (2005 prices). 
Estimation of quality of life
The main measure of effectiveness that would be
used within the economic evaluation is QALYs.
QALYs would be estimated by multiplying the
length of time spent in each health state by a
quality of life weight (a utility value) for that state.
A search for studies on quality of life identified
one study.74 The data came from 165 dialysis
patients and were elicited using the EQ-5D
instrument. Their results indicated that patients
undergoing hospital HD had a utility score of
0.66, satellite HD patients had a value of 0.81,
continuous ambulatory PD patients had a value of
0.71 and continuous cycling PD patients had a
value of 0.81. As these do not come from an RCT,
these utility scores are influenced by the choice of
modality for each patient (i.e. there may be a
selection bias). Although the utility scores for
patients with end-stage renal disease were
identified, there were no data on utilities of people
on dialysis with infections. 
Another further source of utility values was the
data collected by the European Dialysis and Cost
Effectiveness (EURODICE) study. This study
prospectively identified cohorts of patients starting
on HD and PD and collected EQ-5D data from
patients on 1 July 1998 and 31 October 1999
every 6 months for a period of 2–3 years. Health
state utilities were collected from all study
participants including those from two UK centres
(Aberdeen and Dundee). These data had not been
previously reported but were obtained from the
study researchers (Caskey F, Consultant
Nephrologist, Bristol: personal communication,
2005)75,76 and the utilities were derived using the
UK population tariffs.77
The modality of first treatment was assumed to be
the method the patient was receiving at 90 days
and not the initial dialysis method, as many
patients, especially those being referred late to
renal units, undergo a brief period of HD before
being established on PD. Utility scores for this and
three other time points (collected every 6 months)
were estimated from the data provided. Secondary
analysis was also carried out on the scores of
patients who transferred from PD to HD.
However, the numbers of patients changing
treatment modality from PD to HD were very low,
so the estimates were not reliable. Although there
is not much detail on what type of HD and PD was
being administered by the 12th month, EQ-5D
values are similar to these reported by de Wit and
colleagues.74 The utility value for patients
receiving PD was 0.84 and for those receiving HD
it was 0.69. These scores could therefore be used
as the utility scores associated with ‘PD without SA
carriage’, ‘PD with SA carriage’, ‘Temporary HD’,
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TABLE 14 Cost parameters available for use in the hypothetical model
Cost element Value (£) Unit
Peritoneal dialysis 1603 Cost per month
Permanent and temporary haemodialysis 2458 Cost per month
Prophylaxis for S. aureus carriage 15 Cost 
Treatment for S. aureus carriage 15 Cost per course
Treatment of exit-site infection 192 Cost per treatment 
Treatment of tunnel infection  1035 Cost per treatment complication; may require removal of catheter
Catheter replacement  2235 Cost per procedure
Cost of creating access for haemodialysis 2240 Cost per access
Treatment of peritonitis 203 Cost per treatmentand ‘Permanent HD’ in the model, as they are
more representative of the UK population than
those available from de Wit and colleagues.74
These data, however, should be treated with great
caution as they are associated with considerable
imprecision (which, although reported here, would
need to be incorporated into the economic
evaluation) derived from a non-randomised study
and, like the data from de Wit and colleagues,74
will suffer from patient selection bias. 
The EURODICE data provided no information
with which to inform estimates of the utility
associated with infections. Ideally, primary data
collection would be performed to inform this. In
the absence of such data, one approach would be
to perform a sensitivity analysis using a range of
values to explore the impact of this uncertainty on
the results. A second approach would be to
explore the use of other data sets such as the
Health Outcomes Data Repository (eHODAR)
(http://www.crc-limited.co.uk), although it is
unlikely that such sources will contain sufficient
information on the utilities relevant to this study. 
Appendix 7
64E
ight trials evaluated different antibiotic
regimes for the treatment of PD-related
infections and one trial compared intraperitoneal
urokinase with a placebo.
Table 15 provides details, where reported, of the
results for the following outcomes: number of
patients with peritonitis caused by S. aureus;
number of patients to have a primary response or
successful treatment; number of patients for whom
the treatment has failed; peritonitis relapse
(number and specify time to) caused by S. aureus;
and number of patients requiring catheter
removal.
Number of patients with exit-site
and/or tunnel infections caused by
S. aureus
Plum and colleagues78 reported the number of
exit sites with S. aureus carriage as 6/8 versus 4/8;
tunnel erythema before treatment 2/6 versus 1/4
and after treatment 0/6 versus 0/4; and tunnel
drainage before treatment 6/6 versus 4/4 and after
treatment 2/6 versus 1/4. 
Side-effects
One trial79 reported one pseudo-obstruction and
one hypotension as a result of antibiotic use in the
intraperitoneal vancomycin plus gentamicin group
and three nausea and one abdominal swelling in
the oral ciproflaxin group.
Death due to peritonitis caused
by S. aureus
Tong and colleagues86 reported that one death in
the placebo group was due to peritonitis.
No data were reported for the following outcomes:
number of patients requiring catheter replacement
caused by S. aureus; number of patients switching
to HD; hospitalisation rates; quality of life; and
development of antibiotic resistance. 
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